CN1915433A - Relativity between AnnexinA3 and drug resistance of platinum type chemical curing medication for cancer - Google Patents

Abstract

An association between annexin A3 and the resistance of cancer to the chemicotherapeutic Pt medicines, a method for increasing or decreasing said resistance by changing the annexin A3 expression in cells, a method for testing or diagnosing said resistance, the medicines used for said methods and their components, usage and screening method, and the therapeutic method for the cancers, especially ovarian cancer, are disclosed.

Description

The dependency of the platinum-based chemotherapy drug resistance of Annexin A3 and cancer

Technical field

Relate generally to chemotherapeutics drug resistance of the present invention field, more specifically the present invention relates to the dependency of the platinum-based chemotherapy drug resistance of annexin A3 and cancer, relate to by changing annexin A3 in the cell and express the method for the platinum-based chemotherapy drug resistance that improves/reduces cancer and can be used for this method and change medicament, the pharmaceutical composition that comprises this medicament and the described medicament that the annexin A3 in cell expresses and be used to prepare the purposes of the chemical sproof medicine of change cancer and the screening technique of described medicament.In addition, the invention still further relates to be used to detect and/or the prognosis cancer to chemical sproof detection or diagnostic method, medicament, pharmaceutical composition and the test kit of platinum-based chemotherapy medicine.The invention still further relates to the method that is used for the treatment of the cancer patient.In the present invention, described cancer is the cancer of the enough platinum-based chemotherapy Drug therapys of energy, and more preferably described cancer is an ovarian cancer.

Background technology

Ovarian cancer is the first fatal disease of gynecological tumor, and 5 years survival rates of patients with terminal are paced up and down all the time at 15%-20%, and it is the one of the main reasons that causes this situation that tumor cell produces drug resistance for chemotherapeutics.The platinum class combines with DNA and forms cross key, thereby the function of destroying DNA can not be duplicated again, also can suppress RNA and proteinic synthetic during high concentration, medicine is treated in a linearize that is at present the most frequently used treatment ovarian cancer, also is the common drug that other entity tumor of treatment comprises breast carcinoma, pulmonary carcinoma, tumor of testis, head and neck cancer, osteosarcoma, melanoma, the esophageal carcinoma etc.When the platinum class is treated these entity tumors, the drug resistance phenomenon has all appearred, and recurrence just appears in the treatment later stage or the treatment initial stage is just reactionless for tumor control is good promptly to treat the initial stage.Clinical with regard to ovarian cancer for existing clear and definite understanding and the definition of platinum medicine drug resistance, yet illustrating of relevant cisplatin resistance mechanism is but not enough far away.Though at present quite deep for the understanding of tumor drug resistance mechanism from gene level, as MDR-1, LRP-1, MRP-1, GST-pi etc. have become well-known drug resistance related gene.But the result of most researchs shows that the expression of multiple drug resistance related gene in ovarian cancer can not be predicted the drug resistance and the prognosis of tumor well, and it may be one of the main reasons that its corresponding protein level of the abundance of mRNA has discordance.DNA is the carrying person of hereditary information, and protein is only the executor of function.Therefore, need carry out high-throughout technology at protein level and further inquire into resistance mechanism, proteomic techniques provides probability for the functional study of drug resistant gene.

Proteomic techniques is a kind of emerging technology that developed recently gets up, and has been widely used in the every field of basic research, and on the whole, proteomics research mainly comprises the following aspects: 1. marking protein group; 2. functional proteomics; 3. structural protein group.At present proteomic techniques mainly concentrates on the early diagnosis of malignant tumor and screens aspect the tumor markers in the application of ovarian tumor, and still has nothing to do in the research of ovarian cancer drug-resistant mark so far.From the clinical tissue directly research platinum class resistance mechanism of starting with, there are many difficulties such as heterogeneous, that the influence factor is complicated, the experimental technique level is limited, positive findings is easily lost.Therefore, be object of study with cell, progressively extend to clinically, a kind of research thinking of science is provided.

(I～XIII) is that a group relies on Ca in Annexin family ²⁺Phospholipids incorporate albumen, have non-EF hand-type Ca ²⁺Binding site plays a role in regulating cell growth and cellular signal transduction pathways.Annexin A3 is unique member with enzymatic activity in the annexin family, have inhibition of phospholipase A 2 and anticoagulant function, it can also cut off inositol1,2-cyclic phosphate forms inositol 1-phosphate, at [the Ross TS that plays a role aspect the control cell proliferation, et al.J Biol Chem.1991,266 (14): 9086-9092.].Though it extensively is present in vegeto-animal each histoorgan, at final stage annexin A3 predominant expression in neutrophilic granulocyte of differentiation.In the neutrophilic granulocyte that is not upset, it is distributed in endochylema, and content is up to the 1%[Ernst JD of endochylema total protein, et al.J Clin Invest, 1990,85 (4): 1065-1071.].At certain C a ²⁺Under the concentration, annexin A3 can be attached on the Phosphatidylserine of vesicle, the effect between film such as mediation phagosome and lysosomal fusion and granule disappearance and the film.In addition, it can promote gather [Le Cabec V, et al.Biochem J, 1994,303 (Pt 2): the 481-487.] of from human neutrophil isolating specific granule.Recently, there are some researches prove that annexin A3 is a kind of new short angiogenesis factor, it can be by activating the increase that HIF-1 causes VEGF, for neoplasm growth and angiogenesis provide new action target [Park JE, et al.Biochem Biophys Res Commun.2005,337 (4): 1283-1287.].So far, the drug-fast dependency of annexin A3 and chemotherapy of tumors does not still have the research report.

Can not predict the drug resistance and the prognosis of tumor well in order to overcome the expression of drug resistance related gene in cancer, the shortcoming that basic research and clinical treatment are separated, the present inventor has identified first that at protein level albumen annexin A3 is relevant with the platinum-based chemotherapy drug resistance of cancer (especially ovarian cancer), and further be verified clinical, make the expression that can pass through detection annexin A3 predict clinical cancer patient's chemotherapy resistance thus, find drug resistance early, change therapeutic scheme, improve 5 years survival rates, and make the expression of annexin A3 that can be by changing drug-fast clinical cancer patient tumors change the therapeutic effect of platinum medicine this type of patient.In addition, the construction of eukaryon expression plasmid for expressing of the eukaryon expression plasmid of the positive and negative adopted annexin A3 that proposes among the present invention and expression annexin A3 fusion rotein is for the function of studying annexin A3 provides favourable instrument.Moreover the present invention also provides the abductive approach of the anti-cisplatin cell line of ovarian cancer SKOV3/CDDP-P, and the dosage and the mode of simulation clinical treatment ovarian cancer provide the good cell model for further studying clinical drug-resistant.

Summary of the invention

Therefore, one aspect of the present invention relates to, and regulates the method for the platinum-based chemotherapy drug resistance of cancer, comprises the expression that changes annexin A3 in the cancer cell, and wherein preferably, described cancer is an ovarian cancer, and described platinum-based chemotherapy medicine is cisplatin or carboplatin.The method of the present invention can be used for the drug resistance of external adjusting cancerous cell or can be used for regulating in the body cancer patient's drug resistance.

In an embodiment of the method for the present invention, by improving annexin A3 expression raising toleration of cancerous cell in the cancerous cell to the platinum-based chemotherapy medicine, preferably, the annexin A3 that improves in the cell by expression annexin A3 gene in cancerous cell expresses, more preferably wherein by using the plasmid of expressing just annexin A3 gene to improve the content of the annexin A3 in the described cell.

Therefore, the proteic polynucleotide of annexin A3 that the present invention also relates to encode comprise the DNA construct and the expression vector of these polynucleotide, and relate to their purposes in the medicine of the platinum-based chemotherapy drug resistance of preparation raising cancer.In the present invention, annexin A3 albumen comprises that not only natural annexin A3 albumen also comprises the annexin A3 albumen of synthetic (for example passing through genetic engineering method), for example contains the fusion rotein of annexin A3.

In another embodiment of the method for the present invention, by the expression reduction of the annexin A3 in minimizing and/or the anticancer toleration of cancer to the platinum-based chemotherapy medicine, preferably, antisensenucleic acids by expressing annexin A3 in cancerous cell and/or the ribozyme that is specific to annexin A3 reduce and/or the annexin A3 that suppresses in the cell expresses, again the content that reduces the annexin A3 in the cell of DNA construct or the expression vector by use antisence annexin A3 wherein preferably.

Therefore, the present invention also relates to reduce and/or anticancer in the annexin A3 medicament of expressing, for example suppress antisense nucleotide that annexin A3 expresses and the ribozyme of special cutting annexinA3 mRNA; The invention still further relates to the purposes of these medicaments in the medicine of the platinum-based chemotherapy drug resistance of preparation reduction cancer.In the embodiment, according to antisense nucleotide of the present invention, it comprises can specific bond annexin A3 polynucleotide sequence or all or part of nucleotide sequence of any sequence of its complementary series, preferably described antisense nucleotide contains one or more part complementation with annexin A3 polynucleotide, more preferably complementary basically, even more preferably complete complementary sequence area, more preferably, described antisense nucleotide comprises and the complete complementary DNA sequence of total length annexin A3 polynucleotide, preferably, described antisense nucleotide is DNA or RNA or its derivant, most preferably, described antisense nucleotide is included in the expression plasmid that can express it, in the preferred eukaryon expression plasmid.In the embodiment, the ribozyme that can specially cut annexin A3 mRNA according to the present invention has the specific substrate binding site with one or more annexin A3 RNA regional complementarity, and it is in this substrate binding site or have on every side and give this molecule RNA the nucleotide sequence of cleavage activity, and preferably described ribozyme is selected from: hammerhead ribozyme, hair clip type ribozyme, hepatitis D virus type ribozyme, Group I Introns type ribozyme or RNaseP RNA type ribozyme or neurospora VS RNA type ribozyme.

The present invention relates on the other hand, change the chemical sproof method of cancer by aforesaid the present invention and changed cancer cell the toleration of platinum-based chemotherapy medicine, preferably, described cell comprises the expression vector of expressing just annexin A3 or antisense annexin A3, preferably, described carrier is a plasmid.

Further aspect of the present invention relates to, a kind of screening can change the method for cancer to the chemical sproof medicament of platinum-based chemotherapy medicine, wherein said cancer is ovarian cancer preferably, and described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably, and described method comprises step: the candidate is provided medicament; Described candidate's medicament is contacted with cancerous cell; Detect the expression of the annexin A3 in the described cancerous cell; Detected expression and predetermined threshold are compared.Correspondingly, the present invention also relates to also pass through the medicament that screening technique of the present invention obtains.

One aspect of the present invention relates to, a kind of chemical sproof method that detects cancerous cell to the platinum-based chemotherapy medicine, wherein said cancer is ovarian cancer preferably, described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably, described method comprises the expression that detects the annexin A3 in the cancerous cell, with gained expression and predetermined threshold are compared, indicate the drug resistance of ovarian cancer cell thus to the platinum-based chemotherapy medicine.

Another aspect of the present invention relates to, a kind of prediction or the therapeutic effect of prognosis platinum-based chemotherapy medicine in the cancer patient, promptly, the method of cancer diagnosis patient's platinum-based chemotherapy drug resistance, wherein said cancer is ovarian cancer preferably, described platinum-based chemotherapy medicine is cisplatin preferably, carboplatin, described method comprises the expression of the annexin A3 in the tumor tissues that detects the cancer patient, compare with amount and predetermined threshold gained, the therapeutic effect of platinum-based chemotherapy medicine is used in prediction or prognosis to described patient thus, that is prediction patient's platinum-based chemotherapy drug resistance.

In said method of the present invention, be used to detect the step of annexin A3 expression by detecting mRNA level or the protein level of annexin A3; Wherein, preferably, the detection on protein level realizes by antibody or oligonucleotide aptamers, preferably utilizes antibody; And the detection on the mRNA level preferably realizes by Northern trace or PCR method.

Correspondingly, the present invention also relates to detect the medicament that annexin A3 expresses.In one embodiment, described test agents is antibody or its Fab of annexin A3, and wherein said antibody can be monoclonal antibody or polyclonal antibody, and preferably it is a neutralizing antibody.In another embodiment, described test agents is the proteinic oligonucleotide aptamers of specific bond annexin A3, preferably described oligonucleotide aptamers is DNA, preferably, described oligonucleotide aptamers connect or labelling other functional group or molecule, for example sulfydryl, amino, radiosiotope, fluorescein, biotin or enzyme etc.In an embodiment again, described test agents is nucleic probe or primer or its combination that is specific to annexin A3 gene.

The invention still further relates to and aforementionedly can detect medicament that annexin A3 expresses and be used for detecting the platinum-based chemotherapy drug resistance of cancerous cell or cancer diagnosis patient's the detection of platinum-based chemotherapy drug resistance or the purposes of diagnostic kit in preparation.With regard to this purposes of the present invention, described pharmacy optimization is the proteinic antibody of annexin A3, preferred monoclonal antibody; Perhaps described medicament detects the mRNA horizontal expression amount of annexin A3 gene in the cell, preferably is specific to the hybridization probe or the primer of annexin A3 gene.

Further aspect of the present invention relates to the method for the treatment of the cancer patient, comprises step: a) change the method for the platinum-based chemotherapy drug resistance of cancer by the present invention, reduce the toleration of patient to the platinum-based chemotherapy medicine; And b) use the platinum-based chemotherapy medicine to described patient, randomly, the platinum-based chemotherapy Drug tolerance that detects the cancer patient in step (a) before is to determine the drug resistance patient.

Another aspect of the invention relates to the method for the treatment of the cancer patient, and described method comprises: determine patient's platinum-based chemotherapy drug resistance and adjustment patient's platinum-based chemotherapy drug administration scheme according to the present invention.In the present invention in this respect, described adjustment comprises the administration frequency and/or the dosage of replacing taxanes chemotherapeutics, increasing or reducing the taxanes chemotherapeutics, etc.

Others of the present invention also relate to pharmaceutical composition, and it comprises and aforementionedly can change the chemical sproof medicament of cancer of the present invention or aforementionedly can detect the medicament that annexin A3 expresses.In some embodiments of the present invention, described pharmaceutical composition comprises or any combination in antisense nucleotide, ribozyme, antibody and the oligonucleotide aptamers of the DNA, the annexin A3 that express annexin A3.In some embodiments, pharmaceutical composition of the present invention is used to diagnose and/or change the platinum-based chemotherapy drug resistance of cancer, and wherein said cancer is an ovarian cancer.

The present invention relates in one aspect to a kind of method of setting up the strain of platinum-based chemotherapy drug resistance cancer cell at last, comprising: induce cancer cell with heavy dose of platinum-based chemotherapy medicine impact.

Of the present invention aspect all, if applicable, preferably, described cancer is the cancer of the enough platinum-based chemotherapy Drug therapys of energy, as ovarian cancer, breast carcinoma, pulmonary carcinoma, tumor of testis, head and neck cancer, osteosarcoma, melanoma, the esophageal carcinoma etc., preferred ovarian cancer, in one embodiment, preferred epithelial ovarian cancer comprises inner membrance sample cancer, slurry breast carcinoma, adenocarcinoma, transitional cell carcinoma, carcinoma of endometrium, clear cell carcinoma, in another embodiment, preferred people's serous ovarian cancer.

Aspect all, if applicable, preferably, described platinum-based chemotherapy medicine is cisplatin, carboplatin, JM-216, nedaplatin, happy platinum etc., is more preferably cisplatin and carboplatin of the present invention.

The accompanying drawing summary

The heavy dose of impact induced method of Fig. 1 .CDDP sketch map

The low dose of intermittently revulsion sketch map of Fig. 2 .CDDP

Fig. 3 .CDDP is to the dose-effect curve of SKOV3, SKOV3/CDDP-P and SKOV3/CDDP-80

Fig. 4. morphocytology om observation (* 200)

A.SKOV3; B.SKOV3/CDDP-P; C.SKOV3/CDDP-80; D, e, f are a, b, c grow to the cellular morphology of exponential phase

Fig. 5 .a. is followed successively by the cellular morphology (* 1600) of SKOV3 under the scanning electron microscope, SKOV3/CDDP-P and SKOV3/CDDP-80 from left to right

The SKOV3 cell becomes fusiformis, and cell surface microvilli is abundant, and is long and very thin, is evenly distributed, and the equal visible cell of CDDP-P and CDDP-80 surface microvillus is more sparse, distributes and owes even.The CDDP-80 metamorphosis is remarkable, and cell extends to both sides from karyon, and area is bigger.B, c. are followed successively by cellular morphology (b, * 8000 of SKOV3 under the transmission electron microscope, SKOV3/CDDP-P and SKOV3/CDDP-80 from left to right; C, * 22000) visible SKOV3 endochylema contains a large amount of mitochondrions, and CDDP-P and the big form of CDDP-80 nucleus are irregular, bizarre nucleus as seen, the nuclear membrane depression obviously has nuclear bag and nuclear prominent.The chromatin skewness, mitochondrion reduces in the in bulk that condenses that has, endochylema, has a large amount of vesicle spline structures.These vesicle spline structures partly are cavitys, part visible particle sample thing.

The growth curve of Fig. 6 .SKOV3, SKOV3/CDDP-P and SKOV3/CDDP-80

Fig. 7 .RT-PCR measures the expression of MDR1, MRP1, LRP1, GST-pi mRNA

^*Compare with SKOV3 in P＜0.01

^*Compare with SKOV3 and SKOV3/CDDP-80 in P＜0.01

Fig. 8. the expression cartogram of MDR1, MRP1, LRP1, GST-pi mRNA in the different cell lines

^*Compare with SKOV3 in P＜0.01

^*Compare with SKOV3 and SKOV3/CDDP-80 in P＜0.01

Fig. 9 Western blot method is measured MDR1, MRP1, the proteic expression of LRP1, GST-pi

Figure 10. all differences expressing protein particle of four kinds of medicine-resistant cell lines

Figure 11. the expression of protein spots 25 (arrow place) in six kinds of cell line 2-DE collection of illustrative plates is accredited as annexin A3 through MALDI-TOF-MS

The peptide matter finger printing of Figure 12 .MALDI-TOF-MS identification of protein point 25 (annexin A3)

Figure 13. the expression of protein spots 67 (arrow place) in six kinds of cell line 2-DE collection of illustrative plates is accredited as destrin through MALDI-TOF-MS

Figure 14. the expression of protein spots 7 (arrow place) in six kinds of cell line 2-DE collection of illustrative plates is accredited as IDHc through MALDI-TOF-MS

Figure 15. the expression of protein spots 54 (arrow place) in six kinds of cell line 2-DE collection of illustrative plates is accredited as GSTO1-1 through MALDI-TOF-MS

Figure 16. the expression of protein spots 34 (arrow place) in six kinds of cell line 2-DE collection of illustrative plates is accredited as cofilin 1 through MALDI-TOF-MS

Figure 17. quantitative PCR method detects the expression of five species diversity expressing proteins mRNA in six kinds of cell lines

Figure 18 .Western blot method detects the expression of four species diversity expressing proteins in six kinds of cell lines

Figure 19 .pcDNA3.1/myc-His (-) B plasmid map

Figure 20 .pcDB-sense anx3 and pcDB-antisense anx3 plasmid construction schematic flow sheet

Figure 21 .pcDNA3.1 (+) plasmid map

Figure 22 .pcDNA3.1-anx3 plasmid construction schematic flow sheet

Figure 23 .pEGFP-N1 plasmid map

Figure 24 .pEGFP-N1-anx3 plasmid construction schematic flow sheet

Figure 25. cell total rna electrophoretogram, visible 28,16S, 5S band

Figure 26 .RT-PCR method amplification annexin A3 (anx 3)

Lane 1 is the as seen visible bright wisp band at the 1000bp place of template with the SKOV3 cell cDNA

Figure 27 .PCR method and enzyme cutting method are identified the T recombiant plasmid

Lane 1: with pcDB-sense anx3 plasmid is template, and as seen the 1000bp place amplifies the expection band

Lane 2:EcoR I single endonuclease digestion can cut out the purpose band

Lane 3: go the T recombiant plasmid of enzyme action

Figure 28. the comparison result of reorganization T plasmid (pGEM-T-anx3) after checking order in Genebank

Figure 29 .PCR method and enzyme cutting method are identified pcDB-sense anx3 and pcDB-antisense anx3 plasmid

Lane 1: the negative control that does not add the upstream primer

Lane 2: with pcDB-sense anx3 plasmid is template, and as seen the 1000bp place amplifies the expection band

Lane 3: with pcDB-antisense anx3 plasmid is template, and as seen the 1000bp place amplifies the expection band

Lane 4: go the pcDB-antisense anx3 plasmid of enzyme action

The pcDB-sense anx3 plasmid of lane 5:EcoR I single endonuclease digestion can cut out the purpose band

The pcDB-antisense anx3 plasmid of lane 6:EcoR I single endonuclease digestion can cut out the purpose band

Figure 30 .pcDB-antisense anx3 plasmid comparison result in Genebank after checking order

Figure 31 .a.PCR method is identified the pcDNA3.1-anx3 plasmid

Lane 1: with the pcDNA3.1-anx3 plasmid is template, and as seen the 1300bp place amplifies the expection band

B. enzyme cutting method is identified the pcDNA3.1-anx3 plasmid

Lane1:EcoR I single endonuclease digestion can cut out the purpose band

Figure 32 .pcDNA3.1-anx3 plasmid comparison result in Genebank after checking order

Figure 33 .PCR method is identified the pEGFP-N1-anx3 plasmid

Lane 1:pEGFP-N1-anx3 plasmid is a template, and as seen the 1000bp place amplifies the expection band

Figure 34. enzyme cutting method is identified the pEGFP-N1-anx3 plasmid

Lane 1:BamH I single endonuclease digestion is not seen the purpose band

Lane 2:Xho I, the visible purpose band of BamH I double digestion

Figure 35 .pEGFP-N1-anx3 plasmid comparison result in Genebank after checking order

Figure 36 .pEGFP-N1-anx3 plasmid is transfection A2780 respectively, SKOV3 cell, the transfection efficiency (24h after the transfection) that fluorescence microscope is observed down

A, the c:pEGFP-N1-anx3 plasmid is for the transfection situation of SKOV3 cell.The transfection efficiency of carrier pEGFP-N1-anx3 plasmid transfection SKOV3 cell is about 20-25% (* 200);

B, the d:pEGFP-N1-anx3 plasmid is for the transfection situation of A2780 cell.Transfection efficiency behind the carrier pEGFP-N1-anx3 transfection A2780 cell 24 is about 45-55% (* 200)

Figure 37 .SKOV3, the colony form of A2780 cell in screening stable transfection process

Figure 38. stable transfected cells clone's western blot qualification result justice annexin A3 plasmid transfection sensitive cell line SKOV3, A2780, antisense annexin A3 plasmid transfection medicine-resistant cell line SKOV3/CDDP, SKOV3/CBP, A2780/CDDP and A2780/CBP

A.annexin A3; B.beta-actin; C. contrast without cells transfected; M. the cell of the corresponding empty plasmid of transfection contrast; 1-7 is the cell clone of transfection corresponding annexin A3 justice or antisense plasmid

Figure 39 .Annexin A3 immunohistochemical staining result (* 200)

A.annexin A3 dyes negative

B.annexin A3 stained positive, male portion is divided into nucleus

C, d.annexin A3 stained positive, male portion is divided into cytoplasm

The specific embodiment

This description is further elaborated the present invention with regard to the following aspects.

Annexin A3 albumen and coding nucleotide thereof

The annexin A3 of indication of the present invention or annexin A3 protein comprise congener, allelic variant, the function equivalent, particularly conservative variant of annexin A3, preferably refer to people annexinA3 protein.Annexin A3 protein conservative variant comprises and compares with annexin A3 protein disclosed herein and to have one or more (for example 1-20,1-10,1-5) amino acid whose insertion, disappearance and/or the protein that adds.In the present invention, " polypeptide " and " protein " can exchange use, can represent the polypeptide of any length.

Those skilled in the art will understand that polynucleotide can be (coding strand or antisense strand) or the two strands of strand, and can be DNA (genomic DNA, cDNA or synthetic DNA) or RNA molecule.The RNA molecule comprises and contains intron and with the HnRNA molecule corresponding with dna molecular of form one to one with do not contain the mRNA molecule of intron.

Polynucleotide can contain variant or biology or the function equivalent that native sequences (the endogenous sequence of promptly encode annexin A3 protein or its part) maybe can contain this sequence.The polynucleotide variant can contain one or more and substitute, adds, lacks and/or insert, and preferably, these changes are that polynucleotide variant conservative or that these changes produce keeps code book to invent proteinic ability.

When carrying out polynucleotide or peptide sequence relatively the time, if after carrying out the maximum match comparison as follows, nucleotide or aminoacid sequence in two sequences are identical, think that then these two sequences are " unanimities ".

A preferred example that is suitable for determining the algorithm of sequence identity and sequence similarity percent is BLAST and BLAST 2.0 algorithms, and they are described in (1990) J.Mol.Biol.215:403-410 such as (1977) Nucl.Acid.Res.25:3389-3402 such as Altschul and Altschul respectively.Adopt parameter for example described herein, BLAST and BLAST 2.0 can be used for determining the sequence identity percent of polynucleotide of the present invention and polypeptide.Carrying out software that BLAST analyzes can be obtained by the public by state-run biotechnology information centre.

Therefore, the present invention includes polynucleotide and peptide sequence with sequence basically identical disclosed herein, for example when adopting methods described herein (for example to adopt the BLAST of canonical parameter to analyze, be described below) time, compare with polynucleotide of the present invention or peptide sequence and to contain at least 50% sequence identity, preferred at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or those sequences of higher sequence identity.Those skilled in the art will understand, consider the location of codon degeneracy, amino acid similarity, frame etc., can suitably adjust to determine two nucleotide sequence coded proteinic corresponding concordance these values.

In other embodiments, the invention provides contain with the consistent or complementary all lengths continuous sequence of one or more sequence disclosed herein section separate polynucleotide and polypeptide.For example, the invention provides contain one or more sequence disclosed herein at least about 15,20,30,40,50,75,100,150,200,300,400,500 1000 or more a plurality of continuous nucleotide and contain between the polynucleotide of continuous nucleotide of all length placed in the middle.What be easy to understand is, " length placed in the middle " in this article refers to any length between these fiducial values, for example 16,17,18,19 etc.; 21,22,23 etc.; 30,31,32 etc.; 50,51,51,53 etc.; 100,101,102,103 etc.; 150,151,152,153 etc.; Comprise 200-500,500-1, all integers between 000 grade.

Polynucleotide of the present invention or its fragment, no matter how long the code sequence of itself is shown, all can with other DNA sequence, as promoter, polyadenylation signal, extra Restriction Enzyme site, multiple clone site, other combinations such as coding section, so that sizable variation may appear in their whole length.Therefore, expection can be adopted the almost nucleotide fragments of any length, in the scope that its total length preferably is limited in being easy to operate and use in the recombinant DNA program of expectation.For example, expection total length about 10,000, exemplary DNA sections about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base equities (comprising all length placed in the middle) are useful in many embodiments of the present invention.

In other embodiments, the present invention relates to the polynucleotide that can hybridize with polynucleotide provided herein or its fragment or its complementary series down at medium stringent condition (preferred high stringent condition).Hybridization technique is known in biology field.

" stringency " degree of used condition was classified when typically, " hybridization conditions " was according to measurement hybridization.The stringency degree can be a foundation in conjunction with the melting temperature (Tm) of complex or probe with nucleic acid for example.For example, " maximum stringency " typically occurs in about Tm-5 ℃ (being lower than 5 ℃ of probe Tm); " high stringency " occurs in following about 5-10 ℃ of Tm; " medium stringency " occurs in following about 10-20 ℃ of probe Tm; " low stringency " occurs in following about 20-25 ℃ of Tm.As an alternative, perhaps further, hybridization conditions can with the salt of hybridization or ionic strength conditions and/or one or the washing of repeatedly stringency be foundation.For example, the extremely low stringency of 6 * SSC=; 3 * SSC=is low to moderate medium stringency; The medium stringency of 1 * SSC=; 0.5 stringencies such as * SSC=height.On function, can adopt maximum stringency condition to determine and the tight same or near tight same nucleotide sequence of hybridization probe; And adopt high stringency condition to determine to have an appointment 80% or the nucleotide sequence of multisequencing homogeneity more with this probe.

For the application that requires high selectivity, typically expectation adopts relatively restricted condition to form crossbred, for example, selects low relatively salt and/or high-temperature condition.Sambrook etc. (Sambrook, J. etc. (1989) molecular cloning, laboratory manual, Cold Spring HarborPress, Plainview N.Y.) provides the hybridization conditions that comprises medium stringency and high stringency.

For ease of explanation, the suitable moderate stringent condition that is used to detect polynucleotide of the present invention and other multi-nucleotide hybrid comprises: with 5 * SSC, 0.5%SDS, the prewashing of 1.0mM EDTA (pH8.0) solution; Under 50-65 ℃, in 5 * SSC, hybridize and spend the night; Subsequently with contain 2 of 0.1%SDS *, 0.5 * and 0.2 * SSC 65 ℃ of following each washed twice 20 minutes.It will be appreciated by those skilled in the art that and easily to operate the hybridization stringency, as changing the salinity and/or the hybridization temperature of hybridization solution.For example, in another embodiment, the tight hybridization conditions of suitable height comprises above-mentioned condition, and difference is that hybridization temperature is elevated to for example 60-65 ℃ or 65-70 ℃.

Polynucleotide of the present invention and polypeptide can prepare according to methods known in the art.Referring to for example common laboratory manual.

The change of expressing

The annexin A3 that one aspect of the present invention relates to by changing in the cancerous cell expresses, and regulates the platinum-based chemotherapy drug resistance of cancer.

In this regard, the change of described expression comprises to be raised and/or activates and express the platinum-based chemotherapy drug resistance that also increases cancer thus, also comprises downward modulation and/or suppresses and express, and reduces the drug resistance of the platinum-based chemotherapy medicine of cancer thus.The present invention can occur in the chemical sproof adjusting of cancer and externally be applied on the cancerous cell for example to obtain the drug-resistant cell strain or to reduce the drug resistance of primary resistance sexual cell.It is subject with the patient who suffers from described cancer in vivo that the present invention also can take place the chemical sproof adjusting of cancer, to change preferred reduction patient's platinum-based chemotherapy drug resistance.

Here used " rise of expression " or " activation of expression " are meant the level of increase gene expression and/or the level and/or the active level of gene outcome of active gene product.For example, can realize by the modes such as endogenous annexinA3 expression of in cancerous cell, expressing external source annexin A3, enhancing cancerous cell.In the present invention, external source annexin A3 refers to the annexin A3 by the gene engineering introducing; And original annexinA3 in the endogenous annexin A3 phalangeal cell.Any level of destination gene expression and/or the level of active gene product and/or the method for the active level of gene outcome of can increasing well known by persons skilled in the art all is applicable to the present invention in this respect, is also included within the scope of the invention thus.

Here used " downward modulation of expression " or " inhibition of expression " are meant the level of reduction gene expression and/or the level and/or the active level of gene outcome of active gene product.As Angell and Baulcombe (1998-WO9836083), Lowe etc., (1989-WO9853083), Lederer etc., (1999-WO9915682) or Wang etc. (1999-WO9953050) described, by, for example add coded sequence or its part with sense orientation (if causing common inhibition) or antisense orientation with respect to promoter sequence, with pass through, for example insert mutation (for example T-DNA inserts or transposon inserts) or can finish the reduction of expression by the gene silencing strategy.Purpose is that gene construct that silent gene is expressed can have so that the nucleotide sequence (or its one or more parts) of the described gene that justice and/or antisense orientation comprise to be arranged with respect to promoter sequence.The method of another down-regulation of gene expression comprises the application of ribozyme.

Can realize thus regulating by use or make it to be exposed to described The compounds of this invention or medicament to cell, tissue, organ or organism, comprise and reduce active gene product or the active level of gene outcome.

Immunomodulating is the example with another kind of technology of downward modulation active gene product and/or gene outcome activity level ability, comprise the antibody of using or exposing described gene outcome in the level that wherein will regulate described gene outcome and/or the active cell of gene outcome, tissue, organ or organism, or in this cell, tissue, organ or organism, express the antibody of described gene outcome.This antibody comprises single-chain antibody, IgG antibody and fragment thereof.

Can also comprise enhancing/reduction active gene product or the active level of gene outcome by use or make it to be exposed to described gene outcome or its active agonist/antagonist realization adjusting to cell, tissue, organ or organism.This agonist/antagonist comprises protein and the chemical compound of identifying according to described the present invention.

In the context of the invention, imagined the rise/downward modulation of annexin A3 gene expression.The present invention also comprises the rise/downward modulation of annexin A3 activity level.

In addition, can consider to make gene silencing by reorganization.

" recombinase " means site-specific recombinase or transposase." recombination site " means locus specificity recombination site or transposon border sequence." locus specificity recombination event " means by generally by 3 elements: the catalytic incident of system that a pair of DNA sequence (locus specificity recombination sequence or site) and enzyme-specific (site-specific recombinase) are formed.Site-specific recombinase is according to the direction of locus specificity recombination sequence, only the recombining reaction between two locus specificity recombination sequences of catalysis.Under the situation that site-specific recombinase exists,, be inserted in two sequences between the locus specificity recombination site will be inverted when locus specificity recombination sequence during with mutual rightabout orientation (that is, oppositely repeating).If so in a single day the locus specificity sequence interacts with site-specific recombinase with identical mutually direction orientation (that is, repeating in the same way), any intervening sequence will lack.Therefore, if the locus specificity recombination sequence is as two terminal existence of foreign DNA that repeat in the same way in being integrated into the eukaryotic gene group, this integration of so described sequence can be reversed by the interaction of locus specificity recombination sequence with corresponding site-specific recombinase subsequently.

Can utilize a large amount of different site-specific recombinase systems, include but not limited to the Cre/lox system of phage P1, zymic FLP/FRT system, the Gin recombinase of phage Mu, the Pin recombinase of escherichia coli (E.coli), the PinB of Shigella (Shigella), the R/RS system of PinD and PinF and pSR1 plasmid.Recombinase all is intergrase, resolvase or flippase (flippases) usually.And the bispecific recombinase can be with the repetition in the same way of two different loci specificity recombination sites of corresponding bispecific recombinase or is not repeated (indirect repeats) in the same way and unite use (WO99/25840).Two preferred site-specific recombinase systems are phage P1 Cre/lox and yeast FLP/FRT system.In these systems, recombinase (Cre or FLP) and its locus specificity recombination sequence (being respectively lox or FRT) separately interact to be inverted or the excision intervening sequence.

Although the locus specificity recombination sequence must with wait to excise or treat that the end of inverted DNA is connected, the gene of the site-specific recombinase of encoding can be positioned at other place.For example, recombinase gene can exist in the eukaryotic dna or can be provided by the dna fragmentation of introducing afterwards, and this dna fragmentation can be by exchange or by cross pollination or directly introduce in the cell.As alternative scheme, for example, can be by microinjection or particle bombardment with the upright introducing eukaryotic cell that connects of the recombinase protein of basic purification.Typically, the site-specific recombinase coding region adjusting sequence that will be operably connected, this adjusting sequence can make site-specific recombinase express in eukaryotic cells.

When enforcement is of the present invention, preferably, for example pass through the expression of recombinase protein matter in the cell, this protein contacts genic integration site, and promote wherein recombination event, intactly excise genetic factor or alternately stay " footprint " at original integration site, about usually 20 nucleotide are long or longer, come the motion of the induction of genetic factor.Can be by standard nucleic acid hybridization and/or amplification technique to detect mobile genetic element or to comprise these hosts and the host's part that exist evaluation to produce of its gene construct according to the inventive method.As alternative scheme, under transformed host cells, tissue and host's that mobile genetic element has excised situation, can be with footprint in the host genome that stays after this technology for detection excision incident.Term " footprint " is construed as any derivant that refers to mobile genetic element described here or contain the gene construct of this factor as used herein, and excision, disappearance or other removal by mobile genetic element in the previous described gene construct cell transformed genome can produce it.Normally, footprint comprises and is used at least promote that the transposon or the single of recombination site that excise copy.Yet, footprint can comprise other sequence that derives from gene construct, for example, if use, derive from the nucleotide sequence of left margin sequence, right border sequence, origin of replication, recombinase coded sequence or transposase coded sequence, or the nucleotide sequence in other carrier source.Therefore, according to the nucleotide sequence of used gene construct recombination seat or transposon, as, for example, can identify footprint with the corresponding or complementary nucleotide sequence in lox site or frt site.

The invention still further relates to by using antisense technology to suppress annexin A3 in vitro and in vivo.Can utilize antisense technology to form by triple helix or come controlling gene to express by antisense DNA or RNA, these two kinds of methods are combining based on polynucleotide and DNA or RNA all.For example, 5 ' coded portion with the polynucleotide of code book invention polypeptide is used for the antisense RNA nucleotide that design length is about 10-40 base pair.(triple helix is consulted people such as Lee to the DNA nucleotide of the regional complementarity that participation is transcribed in design and the gene, Nucl.Acids Res., 6:3073,1979; People such as Cooney, Science, 241:456,1988; With people such as Dervan, Science, 251:1360,1991), prevent transcribing and generating of annexin A3 thus.Antisense RNA nucleotide and mRNA are hybridized in vivo, and blocking-up mRNA molecule is translated into annexin A3 albumen, and (antisense participates in Okano, J.Neurochem., 56:560,1991; " Oligodeoxynucleotidesas Antisense Inhibitors of Gene Expression " (oligonucleotide is as the antisense inhibitor of gene expression), CRC publishing house, Boca Raton, FL, 1988).

Perhaps, can nucleotide mentioned above be delivered to cell, make antisense RNA or DNA to express in vivo, thereby suppress the generation of annexinA3 in mode mentioned above by the flow process of this area.

Antisense nucleotide

The final result of hereditary information stream is proteinic synthetic.DNA is transcribed into messenger RNA by polymerase, produces folding functional protein through translation then on ribosome.Therefore, several steps that can realize that thereon protein synthesis suppresses are arranged along this path.The encode n DNA section of polypeptide described herein, the same with all such mammalian DNA chains, have by hydrogen bonded two chains together: sense strand and antisense strand.Thymidine in DNA was substituted by uridnine, the messenger RNA of coded polypeptide had and the identical nucleotide sequence of adopted DNA chain is arranged.Therefore, synthetic antisense base sequences will combine with mRNA, and suppress the expression by this mRNA encoded protein matter.

Therefore, making antisense nucleotide targeting mRNA is a mechanism of closing protein synthesis, and becomes a kind of strong targeted therapy method thus.For example, polygalacturonase and 2 type muscarine acetylcholine receptors synthetic is subjected to pointing to their inhibition of the antisense nucleotide of mRNA sequence (United States Patent (USP)s 5,739 separately, 119 and United States Patent (USP) 5,759,829, two parts of documents are intactly incorporated this paper into as a reference hereby).And, adopt cell cycle nucleoprotein, wide spectrum drug resistant gene (MDG1), ICAM-1, E-to select albumen, STK-1, striatum GABAA receptor and people EGF (Jaskulski etc., 1988; Vasanthakumar and Ahmed, 1989; Peris etc., 1998; United States Patent (USP) 5,801,154; United States Patent (USP) 5,789,573; United States Patent (USP) 5,718,709 and United States Patent (USP) 5,610,288, all documents are intactly incorporated this paper into as a reference hereby) also shown the example of Antisense Suppression.

Therefore, in exemplary, the invention provides that contain can specific bond polynucleotide sequence described herein or all or part of nucleotide sequence of any sequence of its complementary series.In one embodiment, this antisense nucleotide contains the DNA or derivatives thereof.In another embodiment, this nucleotide contains the RNA or derivatives thereof.In the 3rd embodiment, this nucleotide is the modifying DNA that contains the main chain of thiophosphate modification.In the 4th kind of embodiment, this nucleotide sequence contains the peptide nucleic acid(PNA) or derivatives thereof.In all cases, preferred compositions contains and one or more part complementations of polynucleotide disclosed herein, complementary basically even more preferably complete complementary sequence area more preferably.Described one or more part can be about 10,15,20,30,40,50,75,100,150,200,300,400,500 or 1000 or more a plurality of continuous nucleotide and continuous nucleotide with all length placed in the middle between them.What be easy to understand is, " length placed in the middle " in this article refers to any length between these fiducial values, for example 16,17,18,19 etc.; 21,22,23 etc.; 30,31,32 etc.; 50,51,51,53 etc.; 100,101,102,103 etc.; 150,151,152,153 etc.; Comprise 200-500,500-1, all integers between 000 grade.Therefore, it is few to about 10, as many as about 1000 or more a plurality of nucleotide to it will be understood by those skilled in the art that nucleotide of the present invention can have.

The selection that is specific to the antisense compositions of designated genetic sequence to selected target sequence (for example is based on, human sequence in the illustrative examples) analysis and the mensuration of secondary structure, Tm, binding energy, relative stability carried out, and the antisense compositions also lacks relatively based on their and forms dimer, hair clip or other ability with the secondary structure of said target mrna specific bond in reduction or obstruction and the host cell and select.

The preferred target region of mRNA camber be those be located on or near the zone of AUG translation initiation codon and those basically with the sequence of the 5 ' regional complementarity of this mRNA.To the analysis of these secondary structures with to the consideration that target site is selected is to adopt the 4th edition OLIGO primer analysis software (Rychlik, 1997) and BLASTN 2.0.5 algorithm software (Altschul etc., 1997) to realize.

The inventor also considers to adopt the antisense delivery method of being undertaken by the small peptide carrier that is called MPG (27 residues).The MPG peptide contains one and derives from the hydrophobic domain of HIV gp41 fusion sequence and the hydrophilic domain (Morris etc., 1997) that derives from SV40 T cell antigen nuclear localization sequence.Illustrate, several MPG peptide molecules can wrap by antisense nucleotide, and they can be delivered in the mammalian cell of cultivation with high relatively efficient (90%) in 1 hour in less than.And, greatly increased the stability of this nucleotide pair nuclease-resistant and the ability (Morris etc., 1997) of crossing over plasma membrane with the interaction of MPG.

Ribozyme

Although protein is used to the catalytic reaction of nucleic acid traditionally always, it is useful in this regard that another kind of macromole has shown.Ribozyme is the RNA-protein complex that cuts nucleic acid in the locus specificity mode.Ribozyme has special catalytic domain, and this catalytic domain has endonuclease enzymatic activity (Kim and Cech, 1987; Gerlach etc., 1987; Forster and Symons, 1987).For example, a lot of ribozymes quicken phosphoester transfer with the specificity of height, usually only cut (Cech etc., 1981 in several phosphate esters of oligonucleotide substrate; Michel and Westhof, 1990; Reinhold-Hurek and Shub, 1992).This specificity quilt is owing to following essential condition, and promptly this substrate combines with the inside homing sequence (" IGS ") of ribozyme by special base pairing interaction before chemical reaction.

Originally, the catalytic reaction of ribozyme is (Joyce, 1989 that are observed as the part that relates to the sequence-specific cutting/coupled reaction of nucleic acid; Cech etc. 1981).For example, United States Patent (USP) 5,354,855 (incorporating this paper hereby into as a reference) were reported, some ribozyme can play the effect of endonuclease, and its sequence-specific is higher than the sequence-specific of known ribonuclease, and approaches the sequence-specific of DNA Restriction Enzyme.Therefore, the gene expression of sequence-specific ribozyme mediation suppresses to be particularly suited for treatment application (Scanlon etc., 1991; Sarver etc., 1990).Recently, report that ribozyme causes hereditary change in its applied some cell line; The gene of these changes comprises the gene of oncogene H-ras, c-fos and HIV.The major part of this work relates to based on special ribozyme and cuts the said target mrna modification that special sudden change codon carries out.

6 kinds of basic variants of present known naturally occurring enzyme RNA.Each all can be under physiological condition the hydrolysis (therefore can cut other RNA molecule) of trans catalysis RNA phosphodiester bond.Generally, enzyme nucleic acid is by at first acting on combining of target RNA.This combination assigns to carry out by the target joint portion of enzyme nucleic acid, and this part is carried out target RNA cutting in this molecule enzyme partly abuts against.Therefore, this enzyme nucleic acid is by at first identification of complementary base pairing, then in conjunction with target RNA, in case with after correct site combines, cut this target RNA by the zymetology effect.To destroy it to the tactic cutting of this target RNA and instruct the synthetic ability of coded albumen.After enzyme nucleic acid is realized combination and cutting to its RNA target, it will be released seeking another target from this RNA, and can repeat combination and the new target of cutting.

The zymologic property of ribozyme is better than many technology, and antisense technology (combining to block its translation with the nucleic acid target simply at this technology amplifying nucleic acid molecule) for example is because realize that the required antisense oligonucleotide concentration of the necessary ribozyme concentration ratio of therapeutic treatment is low.This advantage has reflected the ability that ribozyme works by the zymetology mode.Therefore, a single ribozyme molecule can cut many target RNA molecules.In addition, ribozyme still is a kind of inhibitor of high special, and it suppresses specificity and not only depends on the bonded base pairing mechanism with target RNA, also depends on the mechanism of target RNA being carried out cutting.Single base mispairing or base near cleavage site substitute the catalytic activity that can fully eliminate ribozyme.Similar mispairing in antisense molecule does not hinder its effect (Woolf etc., 1992).Therefore, the specificity of ribozyme effect than with the effect specificity height of the bonded antisense oligonucleotide in identical RNA site.

In the motif of tup, hair clip, hepatitis D virus, Group I Introns or RNaseP RNA (relevant) or neurospora (Neurospora) VS RNA, can form the enzyme nucleic acid molecules with the RNA homing sequence.The example of tup motif is described in (1992) such as Rossi.The example of hair clip motif is described in (the open text EP 0360257 of european patent application), Hampel and (1990) and United States Patent (USP)s 5,631,359 (incorporating this paper hereby into as a reference) such as Tritz (1989), Hampel such as Hampel.The example of hepatitis D virus motif is described in Perrotta and Been (1992); The example of RNaseP motif is described in (1983) such as Guerrier-Takada; The ribozyme motif of neurospora VS RNA is described in Collins (Saville and Collins, 1990; Saville and Collins, 1991; Collins and Olive, 1993); The example of Group I Introns is described in United States Patent (USP) 4,987,071 (incorporating this paper hereby into as a reference).For enzyme nucleic acid molecules of the present invention important only be, this molecule has the specific substrate binding site with one or more target gene RNA regional complementarity, and it is in this substrate binding site or have on every side and give this molecule RNA the nucleotide sequence of cleavage activity.Therefore, need not structure qualification with this ribozyme in the mentioned concrete motif of this paper.

In certain embodiments, preparation may be important to the enzyme cutting agent that the RNA of purpose target (one of them sequence for example disclosed herein) shows high degree of specificity.This enzyme nucleic acid molecules preferred orientation is in the highly conserved sequence district of said target mrna.Can send these external enzyme nucleic acid molecules to specific cells as required.Perhaps, can be from DNA or the RNA vector expression ribozyme that is delivered to specific cells.

Little enzyme nucleic acid motif (for example motif of tup or hairpin structure) also can be used for external sending.The simple structure of these molecules has increased the ability that this enzyme nucleic acid is invaded the target area of mRNA structure.Perhaps, can be in cell express catalytic RNA molecule (Scanlon etc. for example, 1991 from eukaryotic promoter; Kashani-Sabet etc., 1992; Dropulic etc., 1992; Weerasinghe etc., 1991; Ojwang etc., 1992; Chen etc., 1992; Sarver etc., 1990).Those skilled in the art understand that any ribozyme can be expressed from the dna vector that is fit in eukaryotic cell.The activity of these ribozymes can discharge in primary transcribe by means of second kind of ribozyme by them and be improved (the open text WO93/23569 of international patent application, with the open text WO 94/02595 of international patent application, both all take this to incorporate this paper into as a reference; Ohkawa etc., 1992; Taira etc., 1991; With Ventura etc., 1993).

Ribozyme directly can be added in the target cell, maybe can make it mix or be packaged in the liposome or otherwise with cation lipid, composite of lipid and be delivered in the target cell.This RNA or RNA complex can pass through injection, aerosol suction, infusion pump or support, and to mix or not mix the form in the biopolymer, linked groups is given in the interior local application of stripped or body.

Ribozyme can be by open text WO 93/23569 of international patent application and the described design of WO 94/02595 (all being incorporated herein by reference), and by described synthetic be used for external and body in test.Also can optimize these ribozymes is convenient to send.Although instantiation is provided, those skilled in the art will know, and that can adopt other species in case of necessity is equal to the RNA target.

Can analyze tup or hair clip ribozyme individually by computer folding (Jaeger etc., 1989), whether be folded into suitable secondary structure to estimate this ribozyme sequence.To get rid of outside consideration at those ribozymes that have unfavorable intermolecular interaction between brachium conjunctivum and the catalytic core.Can select different brachium conjunctivum length to optimize activity.Generally, about at least 5 base can be in conjunction with target RNA on every arm, or otherwise interacts with target RNA.

Ribozyme with tup or hair clip motif can be designed to mRNA information in the annealing of each site, and can carry out chemosynthesis to it.Used synthetic method is with (1990) described synthetic programs of normal ribonucleic acid that is used for such as (1987) such as Usman and Scaringe; and adopt common nucleic acid protection and coupling group; for example 5 ' end adopts dimethoxytrityl, and 3 ' the terminal phosphoramidite that adopts.Typically, average progressively coupling output is greater than 98%.The hair clip ribozyme can divide two parts synthetic, anneals then to rebuild active ribozyme (Chowrira and Burke, 1992).Can modify widely ribozyme, so that by adopting nuclease resistance group to increase stability (summary is referring to for example Usman and Cedergren, 1992) as 2 '-amino, 2 '-C-pi-allyl, 2 '-fluorine, 2 '-o-methyl, 2 '-H.Ribozyme can adopt conventional method to pass through gel electrophoresis or obtain purification by high pressure liquid chromatography (HPLC), and is resuspended in the water.

The activity of ribozyme can be optimized by the ribozyme that the length or the chemosynthesis of change ribozyme brachium conjunctivum are modified, and described being modified with prevents that this ribozyme is subjected to the modification of serum ribonucleic acid enzymatic degradation and (sees for example open text WO 92/07065 of international patent application; Perrault etc., 1990; Pieken etc., 1991; Usman and Cedergren, 1992; The open text WO 93/15187 of international patent application; The open text WO 91/03162 of international patent application; The open text 92110298.4 of european patent application; United States Patent (USP) 5,334,711; With the open text WO 94/13688 of international patent application, they have described the various chemical modifications that can carry out the sugar moieties of enzyme RNA molecule), strengthen the modification of the effectiveness of ribozyme in cell and in order to shorten the RNA generated time and to reduce chemical essential condition and the removing of the stem district II base of carrying out.

Sullivan etc. (the open text WO 94/02595 of international patent application) have described the conventional method of sending enzyme RNA molecule.Ribozyme can be administered to cell by the known several different methods of those skilled in the art.These methods include but not limited to be packaged in the liposome, ionotherapy or mix in other carrier (as hydrogel, cyclodextrin, the miniature capsule of biodegradable (nanocapsule) and bioadhesion microsphere).For certain situation, can give cell or tissue with the ribozyme ex vivo delivered being with or without under the situation of above-mentioned carrier directly.Perhaps, can or utilize conduit, infusion pump or support, carry out the local delivery of RNA/ carrier combinations by direct suction, direct injection.Other route of delivery includes, but not limited in the blood vessel, intramuscular, subcutaneous or joint injection, and aerosol sucks, and oral (tablet or pill) sends in partial, system, eye, intraperitoneal and/or the sheath.The more detailed description of sending and using about ribozyme discloses text WO 94/02595 and the open text WO 93/23569 of international patent application referring to international patent application, and all documents are all incorporated this paper into as a reference hereby.

Other method at cell inner accumulated high concentration ribozyme is that this ribozyme coded sequence is mixed in the DNA expression vector.Transcribing of ribozyme sequence by promoters driven at eucaryotic RNA polymerase I (pol I), rna plymerase ii (pol II) or rna plymerase iii (pol III).Will be from pol II or pol III promoter acquisition transcript with high level expression all cells; Near the character of the sequential gene regulating that will exist the level of specified pol II promoter will depend in the designated cell type (increasing son, silencer etc.).Also can adopt the prokaryotic rna polymerase promoter, as long as in suitable cell, there is this prokaryotic rna polymerase to express (Elroy-Stein and Moss, 1990; Gao and Huang, 1993; Lieber etc., 1993; Zhou etc., 1990).Can mammalian cell, bring into play function (Kashani-Saber etc. for example, 1992 from the ribozyme of these promoter expressions; Ojwang etc., 1992; Chen etc., 1992; Yu etc., 1993; L ' Huillier etc., 1992; Lisziewicz etc., 1993).These transcript units can be mixed the multiple carrier that is used for importing mammalian cell, these carriers comprise, but be not limited to plasmid DNA carrier, viral DNA carrier (for example adenovirus or gland relevant viral vector) or viral rna vector (for example retrovirus, semliki forest virus, sindbis virus carrier).

Ribozyme can be as genetic drift (geneticdrift) and the sudden change in the diagnostic tool inspection diseased cells.They can also be used to estimate the level of target RNA molecule.Ribozyme activity and the interstructural close relation of target RNA make can detect sudden change in having changed any zone of this molecule of target RNA base pairing and three dimensional structure.By adopting multiple ribozyme, can give in external and cell and tissue the important nucleotide of the 26S Proteasome Structure and Function of RNA changed and map.Can adopt ribozyme the cutting inhibition of gene expression of target RNA and (basically) to be determined to specify in the disease process effect of gene outcome.In this way, other hereditary target can be defined as the important mediator of this disease.These researchs will cause the better healing to this disease process by the probability that Comprehensive Treatment (for example heterogeneic multiple ribozyme of targeting, the intermittent treatment of carrying out with the link coupled ribozyme of known small molecules inhibitor or associating ribozyme and/or other chemistry or biomolecule) is provided.The external application of other of ribozyme is well known in the art, comprises the existence that detects the mRNA relevant with the IL-5 relevant disease.This RNA detects by adopting standard method to measure existing of cleaved products after handling with ribozyme.

Bonding agent

The present invention also provides specifically the medicament with annexin A3 protein bound, for example antibody and its Fab.In this article, can detected level if antibody or its Fab and the proteinic reaction of annexinA3 (in ELISA for example) are in, and when the proteinic reaction of nothing to do with can not be detected under condition of similarity, then be considered to and annexin A3 protein " specific bond "." combination " used herein is meant the non-covalent connection between two independent molecules so that forms complex.Binding ability can be estimated by for example measuring the binding constant that forms this complex.Binding constant is the value that obtains when the concentration product with each composition removes the concentration of this complex.Usually, in the context of the present invention, when the binding constant that forms complex greater than about 10 ³During L/mol, two chemical compounds are considered to " combining ".This binding constant can adopt method well known in the art to measure.

Adopt representative assay method provided herein, bonding agent can also be distinguished the toleration whether cancer patient/cancerous cell has tolerance platinum-based chemotherapy medicine.In other words, the signal that the indication drug resistance exists will be at least about 20% drug resistance patient/cancerous cell, produced with antibody or other bonding agent of annexin A3 protein bound, and the non-existent signal of indication drug resistance will be at least about 90% responsive patient/cancerous cell, produced.In order to determine whether bonding agent satisfies this requirement, can be determined at from (determining) drug resistance and responsive patient's the biological sample (for example tumor biopsy tissue) or in drug resistance or responsive cancerous cell, whether exist and the bonded polypeptide of this bonding agent by methods described herein with the standard clinical check.Clearly, the quantity of the drug resistance of analysis and responsive sample should have significance,statistical.Each bonding agent all should satisfy above standard; Yet, will be apparent to those skilled in the art that to unite and use a plurality of bonding agent to improve sensitivity.

Satisfying the above any medicament that requires can be bonding agent.For example, bonding agent can be ribosome, RNA molecule or the polypeptide that contains or do not contain peptide components.In a preferred embodiment, bonding agent is antibody or its Fab.The preparation of antibody can be adopted any one in the known multiple technologies of those of ordinary skills.See for example Harlow and Lane, antibody: laboratory manual (Antibodies:A Laboratory Manual), Cold SpringHarbor Laboratory, 1988.Usually, can prepare antibody by cell culture technology, these technology comprise by preparation monoclonal antibody described herein, or antibacterial or mammalian cell host by being fit to the antibody gene transfection, can produce recombinant antibodies so that make.In a technology, at first contain the immunogen of polypeptide of the present invention to any injection in the multiple mammal (for example mice, rat, rabbit, sheep or goat).In this step, can polypeptide of the present invention is not modified as immunogen.Perhaps, especially for short relatively polypeptide, if with this polypeptide and carrier protein, for example bovine serum albumin or keyhole limpet hemocyanin link together, and then can cause splendid immunne response.Inject this immunogen for this animal reservoir, and preferably mix one or booster immunization repeatedly, regularly take the blood of this animal then according to predetermined timetable.Can carry out affinity chromatograph by for example adopting with link coupled this polypeptide of suitable solid support from antiserum then, purification has specific polyclonal antibody to this polypeptide.

The purpose antigen polypeptide is had specific monoclonal antibody can adopt for example technology (Eur.J.Immunol.6:511-519,1976) of Kohler and Milstein, and modification method prepares.In brief, these methods relate to the immortalized cell line that preparation can produce and had the expectation specificity antibody of the reactivity of desired polypeptides (promptly with).Can prepare these cell line from for example splenocyte available from immune as stated above animal.Then by for example with myeloma cell's fusion partner, preferably with the isogenic myeloma cell of this immune animal, merge, make this splenocyte immortalization.Can adopt multiple integration technology.For example, can be with this splenocyte and myeloma cell and nonionic detergent mixed for several minutes, be layered on low-density then and support hybrid cell and do not support on the selection culture medium that the myeloma cell grows.Preferred triage techniques has adopted HAT (hypoxanthine, aminopterin, thymidine) screening.After the sufficiently long time, be generally about 1-2 week, can be observed the hybrid colony.Select single colony, and it is active to test combining of its culture supernatants and polypeptide of the present invention.Preferably have high response and specific hybridoma.

Can from the supernatant of the hybridoma colony cultivated, separate monoclonal antibody.In addition, can also adopt various technology to increase output, for example this hybridoma cell line is injected into for example intraperitoneal of mice of suitable vertebrate host.Can from ascites or blood, gather in the crops monoclonal antibody then.Can for example chromatography, gel filtration, precipitation and extracting be removed impurity from these antibody by routine techniques.Polypeptide of the present invention can be used for for example affinity chromatograph step of purification process.

In certain embodiments, may preferably adopt antigen-binding fragments of antibodies.These fragments comprise the Fab fragment, and they can adopt the standard technique preparation.In brief, can pass through on A albumen pearl post by affinity chromatograph purification immunoglobulin (Harlow and Lane, antibody: laboratory manual, Cold Spring Harbor Laboratory from rabbit anteserum, 1988), produce Fab and Fc fragment by papain digestion then.This Fab can separate by affinity chromatograph on A albumen pearl post with the Fc fragment.

Monoclonal antibody of the present invention can be coupled at one or more therapeutic agent.The therapeutic agent of Shi Heing comprises radionuclide, differentiating inducer, medicine, toxin and their derivant in this regard.Preferred radionuclide comprises ⁹⁰Y, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At and ²¹²Bi.Preferred medicine comprises methotrexate, reaches the analog of pyrimidine and purine.Preferred differentiating inducer comprises Buddhist ripple ester and butanoic acid.Preferred toxin comprises ricin, abrin, diphtheria toxin, diphtherotoxin, cholera toxin, gelonin, pseudomonas extracellular toxin, Shigellae toxin and pokeweed antiviral protein.

The oligonucleotide aptamers

The SELEX technology is a kind of new combinatorial chemistry technique of development in recent years research nucleic acid structure, function and the evolution etc. of getting up, it not only has good application at aspects such as basic research, biological screenings, and (the Brody EN ﹠amp that also shows wide prospect aspect clinical diagnosis; Gold L, J.Biotechnol., 2000,75:5-13).The oligonucleotide aptamer that filters out (aptamer) but high-affinity with discern different molecules with high specificity.Its affinity and specificity can compare favourably with antibody, are considered to a kind of novel agent of " challenge " antibody status, play an increasingly important role in the diagnosis of disease and treatment.The SELEX technology generally needs number wheel or tens of the wheel just can obtain its corresponding aglucon.Recently, Santa-Coloma TA etc. has reported high specific " polyclonal oligobody (polyclone oligonucleotide aptamers) ", " monoclonal oligobody (monoclonal oligonucleotide aptamers) " or " synthetic oligobody (synthetic oligonucleotide aptamers) " (the BianchiniM et al with the preparation of target handoff technique, J.Immunol.methods, 2001,252:191-197) can discern corresponding proteins matter specifically, be applied to Western blotting, SABC, co-immunoprecipitation etc. and analyze in the experiment.

Regulate the screening of the chemical sproof medicament of platinum chemotherapeutics

To obtain in this screening technique of the present invention or compounds identified can be can be in conjunction with any nucleic acid of the present invention, peptide or proteinic chemical compound.With the chemical compound that other purpose chemical compound of identifying is regulator gene or protein expression of the present invention, the effect by described chemical compound increases or reduces described gene or protein expression like this.As replacement scheme, this chemical compound can be by increasing or reduce any its effect of activity of proteins performance of the present invention.

For example at sample, for example derive from the cell extract of animal and can comprise described a kind of chemical compound or described multiple chemical compound.And described chemical compound can be known in the art, but does not know that up to now it has the ability that suppresses or activate annexin A3 interacting protein.Reactant mixture can be that cell-free extract maybe can comprise the cell or tissue culture.The suitable equipment that is used for the inventive method is well known by persons skilled in the art, and, usually, at Alberts etc., Molecular Biology of the Cell, the 3rd edition (1994) particularly are described in 17 chapters.Multiple chemical compound is passable, for example adds in reactant mixture, the cell culture medium or inject to enter in the cell.

If identified the sample that contains chemical compound or multiple chemical compound in the methods of the invention, the primary sample separating compound that can contain chemical compound that can antagonist/agonist effect so from evaluation, if perhaps, for example primary sample is made up of multiple different chemical compounds, people can further segment primary sample, with the quantity of the different material that reduces each sample, and utilize the segmentation of primary sample partly to repeat this method.Complexity per sample can be carried out above-mentioned steps several times, preferably, and till the sample of identifying according to the inventive method only contains limited quantity or only contains a kind of material.Preferably, described sample contains the material with similar chemistry and/or physical characteristic, and most preferably described material is identical.Preferably, further made the form that is suitable for to animals administer according to said method compounds identified or derivatives thereof.

As candidate's medicament of the inventive method, the segmental mold that can utilize suitable computer program can carry out protein structure motif of the present invention fit computer design again (Olszewski, Proteins 25 (1996), 286-299; Hoffman, Comput.Appl.Biosci.1 (1995), 675-679) or can obtain by chemical compound combinatorial library screening.Computer Simulation on Protein Folding can be used for conformation and energy spectrometer (Monge, J.Mol.Biol.247 (1995), the 995-1012 of detailed peptide and protein model; Renouf, Adv.Exp.Med.Biol.376 (1995), 37-45).Especially, by the CAR complementary peptide sequences, the program that is fit to can be used for the evaluation of interaction sites of annexin A3/ phosphorylation annexin A3, its part or other interacting protein, and (Fassina, Immunomethods 5 (1994), 114-120).And, in background technology, for example at Berry, Biochem.Soc.Trans.22 (1994), 1033-1036; Wodak, Ann, N.Y.Acac.Sci.501 (1987), 1-13; Pabo, Biochemistry 25 (1986), described the computer system that is fit to that is used for protein and peptide design among the 5987-5991.Can be used for the preparation of protein for example of the present invention or its segmental peptide mimics from the result of aforementioned calculation machine analysis acquisition.The false peptide analogues of this protein natural acid sequence can simulate very effectively parent's protein (Benkirane, J.Biol.Chem.271 (1996), 33218-33224).For example, mixing of the achirality Ω-amino acid residue that obtains easily in protein or its fragment will cause the displacement of aliphatic chain polymethylene unit to amino key, therefore the convenient strategy that makes up peptide mimics is provided, and (Banerjee, Biopolymers 39 (1996), 769-777).Also described in the prior art the oligopeptide hormone in other system superactivity peptide analogy thing (Zhang, Biochem.Biophys.Res.Commun.224 (1996), 327-331).Also can and detect and obtain chemical compound thus by the synthetic peptide mimics combinatorial library of continuous amino-alkylation, for example their combination, kinase inhibition and/or immunological characteristic are identified the peptide mimics that protein of the present invention is fit to.In prior art, for example at Ostresh, Methods inEnzymology 267 (1996), 220-234 and Dorner, and Bioorg.Med.Chem.4 (1996) has described method and purposes that the peptide mimics combinatorial library produces among the 709-715.And, can utilize proteinic three-dimensional of the present invention and/or crystal structure design biological activity peptide mimics inhibitor (Rose, Biochemistry 35 (1996), 12933-12944; Ruterber, Bioorg.Med.Chem.4 (1996), 1545-1558).

The present invention correspondingly also provides the pharmaceutical composition and the purposes of described medicament in preparation adjusting drug resistance of the present invention of regulating the chemical sproof medicament of the present invention and comprising described medicament.

Chemical sproof detection and diagnosis

Usually, can based on JEG-3 or from the tumor biopsy tissue that the patient obtains the content of annexin A3 Protein content and/or these proteinic polynucleotide of encoding, detect described cancerous cell and patient and whether have the platinum-based chemotherapy drug resistance.General bonding agent provided herein can the detection of biological sample in the bonded antigenic level of this medicament.Polynucleotide primer and probe can be used to detect the level of the proteinic mRNA of codes for tumor, and whether this level has also indicated chemical sproof existence.

For the polypeptide sign in adopting the bonding agent test sample, there is the known mensuration form of multiple those of ordinary skills to use.See for example Harlow and Lane, antibody: laboratory manual, Cold Spring Harbor Laboratory, 1988.Usually, JEG-3 and cancer patient's platinum chemotherapeutics drug resistance can be determined by following steps: (a) tumor sample that contacts JEG-3 or obtain from the patient with bonding agent; (b) in the test sample with the level of the bonded polypeptide of this bonding agent; (c) this polypeptide level and predetermined cutoff value are compared.

In a preferred embodiment, this mensuration relates to and adopts the bonding agent be fixed on the solid support in conjunction with this polypeptide, and separates this polypeptide from the sample residue.Adopt then and contain reporter group and special and this bonded polypeptide of the bonded detectable detection of this bonding agent/polypeptide complex.These detectable for example can contain, with the bonding agent of this polypeptide specific bond or with antibody or other medicament of this bonding agent specific bond, for example anti-immunoglobulin, G albumen, A albumen or agglutinin.Perhaps, can utilize competition assay, use the reporter group labeling polypeptide in the method, and at the immobilization bonding agent after sample is hatched, allow this polypeptide and this bonding agent combination.Composition in this sample has been indicated the reactivity of this sample and this immobilization bonding agent to this labeling polypeptide and the bonded inhibition degree of this bonding agent.The polypeptide that is suitable for these assay methods comprises above-described total length annexin A3 protein and itself and this bonded part of bonding agent.

As noted above, all right, perhaps as an alternative scheme can, based on the horizontal detection drug resistance of coding annexin A3 proteinic mRNA in the cancerous cell sample.For example, can adopt at least two oligonucleotide primers amplifications to derive from the part of the tumor cDNA of sample in based on the mensuration of polymerase chain reaction, wherein at least one in this oligonucleotide primers is special (promptly can hybridize with it) to the proteinic polynucleotide of this annexin A3 of encoding.Adopt technology well known in the art then, the example gel electrophoresis separates and detects the cDNA of this amplification.Similarly, can in hybridization assays (hybridization assay), adopt oligonucleotide probe special and the proteinic multi-nucleotide hybrid of coding annexin A3, whether have the polynucleotide of this oncoprotein matter of encoding in the detection of biological sample.

The present invention also is provided for the test kit of any above detection and diagnostic method.These test kits typically contain and carry out necessary two or more compositions of diagnostic assay.These compositions can be chemical compound, reagent, container and/or equipment.For example, a container in the test kit can contain special and monoclonal antibody or its fragment annexin A3 protein bound, and perhaps a container in this test kit can contain nucleic probe or the primer that is specific to annexin A3 coded sequence.

Treatment of cancer

In others of the present invention, relate to the annexin A3 that finds first based on the inventor and the chemical sproof dependency of platinum chemotherapeutics of cancer, the treatment cancer.In these methods, typically identify patient's drug resistance by diagnostic method of the present invention, determine patient's platinum-based chemotherapy medicament administration scheme then according to the drug resistance result.In one embodiment, Therapeutic Method of the present invention comprises after being defined as possessing chemical sproof patient and reducing its drug resistance by the chemical sproof method of adjusting of the present invention, uses the platinum-based chemotherapy medicine again.In another embodiment, Therapeutic Method of the present invention comprises according to the drug resistance result who determines, the dosage of adjustment platinum-based chemotherapy medicine, administration frequency etc.In the embodiment, Therapeutic Method of the present invention comprises that according to the drug resistance result who determines, alternative platinum-based chemotherapy medicine is used for this patient's treatment again." patient " used herein is meant any Homoiotherm, and be as mammal, preferred human.

Pharmaceutical composition

In other embodiments, the present invention relates to one or more polynucleotide disclosed herein, polypeptide, antisense oligonucleotide, ribozyme, oligonucleotide aptamers and/or the preparation of antibody in pharmaceutically suitable carrier or excipient, be used for separately or the diagnosis/Therapeutic Method of uniting one or more other form is administered to cell or animal.In the embodiment, pharmaceutical composition of the present invention can be used to diagnose the patient's of the present invention platinum chemotherapeutics drug resistance and the therapeutic effect of the described chemotherapeutics of prediction/prognosis.In another embodiment, pharmaceutical composition of the present invention can be used to adjust patient's of the present invention platinum chemotherapeutics drug resistance, in the case, preferably, pharmaceutical composition of the present invention is with targeting patient tumors cell and cause annexin A3 in the tumor cell to express changing the mode of (preferred downward modulation) to realize the chemical sproof adjustment to the patient.

The preparation of pharmaceutically acceptable excipient and carrier solution is well known to those skilled in the art.Equally, the development for the suitable administration of using concrete compositions described herein in various therapeutic schemes and therapeutic scheme (comprising for example oral, parenteral route, intravenous, intranasal and intramuscular administration and medicine preparation) also is well known to those skilled in the art.

The route of administration of therapeutic combination described herein and frequency and dosage will vary with each individual, and can be determined by the clinicist.Usually, can use these pharmaceutical compositions by injection (for example Intradermal, intramuscular, intravenous or subcutaneous), nasal (for example by sucking) or oral.Usually, suitable dosage and therapeutic scheme provide the active principle that is enough to obtain to treat benefit, and it can be by determining and not treating the patient and compare clinical effectiveness that to improve appear in the patient through treatment and monitor or determine.

Further the present invention is illustrated by the following examples.But should be appreciated that these embodiment are construed as limiting scope of the present invention never in any form.

Embodiment

In the application's research, the present application people utilizes the difference of protein expression profile between proteomic techniques research drug resistance and the sensitive cells first, and then seeks possible drug resistance mark.

At first set up the cell line of the inductive ovarian cancer cell line SKOV3 tolerance of heavy dose of ballistic method and low dose of batch process cisplatin, by detection to the biological characteristics of two kinds of cell lines, find that the different mode of inducing of identical medicine has different influences for the expression of drug resistant gene, the easier generation drug resistance of low dose of batch process.And for research platinum class resistance mechanism has been set up the good cell model.

Secondly, with two kinds of ovarian cancer sensitive cell line SKOV3 and A2780, four kinds of medicine-resistant cell line SKOV3/CDDP, SKOV3/CBP, A2780/CDDP, A2780/CBP are object of study, set up protein expression profile separately by two dimensional gel electrophore-sis, the protein of statistical analysis differential expression carries out mass spectrum and identifies.Protein annexin A3, destrin, IDHc, GSTO1-1 and cofilin 1 differential expression in mdr cell more than three kinds.Wherein, find first that annexin A3 expresses all significantly to raise in mdr cell, simultaneously by RT-PCR and two kinds of method simultaneous verifications of western blot this result.

For understanding annexin A3 and chemical sproof relation, utilize technique for gene engineering, with pcDNA3.1/myc-His (-) B is carrier, the eukaryon expression plasmid of construction expression antisense annexin A3, with pcDNA3.1 (+) is carrier, the eukaryon expression plasmid of construction expression justice annexin A3, and be carrier with pEGFP-N1, the eukaryon expression plasmid of construction expression annexin A3 fusion rotein is by each cell line of liposome-mediated plasmid DNA transfection.By pEGFP-N1-annexin A3 difference transfection SKOV3 and A2780 cell line, the transfection efficiency that detects SKOV3 and A2780 is respectively 20-25% and 45-55%.The drug resistance index rose 2～4 times after sensitive cells tied up to transfection justice annexin A3 plasmid behind the stable transfection, mdr cell ties up to behind the transfection antisense annexin A3 plasmid about 2 times of drug resistance index decreased, has proved that the rise of annexinA3 or downward modulation are relevant with drug resistance.

For at clinical verification annexin A3 and the drug-fast dependency of platinum class, collecting respectively and adopting the platinum class in the clinical ovarian cancer treatment is main chemotherapy sensitivity and drug resistance patient's operation case, paraffin section is carried out the SABC test of annexin A3.The double-blind method microscopically is read sheet and evaluation, adopt the rank test statistics chemotherapy sensitivity of ranked data and drug resistance patient's annexin A3 expression, U value=139, P value=0.035＜0.05, illustrate between chemotherapy sensitivity person and drug resistance person's the annexinA3 expression and have significant difference, chemotherapy resistance person's annexin A3 expression is higher than responsive person, has verified that annexin A3 is a kind of ovarian cancer platinum class drug resistance associated protein.

The foundation and the evaluation of embodiment one epithelial ovarian cancer medicine-resistant cell line

(1) experimental technique

One) cell line and cell culture

People's serous ovarian cancer SKOV3 cell line is purchased the preclinical medicine cell centre in the Chinese Academy of Medical Sciences.Cell is adherent growth in the DMEM that contains 10% hyclone (HG) (U.S. Gibco company) culture fluid, places 37 ℃, 5%CO ₂Cultivate in the saturated humidity incubator, 0.25% trypsinization goes down to posterity.

Two) foundation of medicine-resistant cell line

1. heavy dose of impact induced method called after SKOV3/CDDP-P cell.After in culture medium, adding 100 μ mol/L CDDP (cisplatin, FH section ancient cooking vessel company limited) 2h, abandon the pastille culture medium, add and do not contain the medicine culture medium, place 37 ℃, 5%CO ₂Continue in the saturated humidity incubator to cultivate, treat that cell grows to exponential phase (density is to 70%-80%), repeated doses is impacted.100 μ mol/L impact 20 times, and 200 μ mol/L impact 10 times.Delivery time gradually becomes 4～5d by 4 initial weeks.Fig. 1 is seen at concrete administration time and interval.

2. low dose of intermittently revulsion called after SKOV3/CDDP-80.In culture medium, add the CDDP of 10 μ mol/L, place 37 ℃, 5%CO ₂Cultivate 48h in the saturated humidity incubator, abandon the pastille culture medium, add and do not contain the medicine culture medium, place 37 ℃, 5%CO ₂Continue in the saturated humidity incubator to cultivate, treat that cell grows to exponential phase, repeated doses is induced.Dosage is that 10,20,40 and 80 μ mol/L respectively increase progressively for 10 times.Delivery time gradually became for 1～2 week by 6 initial weeks.Fig. 2 is seen at concrete administration time and interval.

After the cell induction success, cell was cultivated 2 months in the culture medium of no medicine, carried out every experiment again.

Three) drug sensitivity test

Get cell exponential phase of growth, make single cell suspension after the trypsinization, by 2000 cells/well/100 μ l, every kind of cell is established 6 parallel holes by each concentration, 12 of control wells, do not add medicine, wherein 6 negative contrasts in hole (add cell, do not add medicine), 6 holes are blank (only adding culture medium).37 ℃, 5%CO ₂Cultivate and add CDPP after 24 hours, doubly be diluted to 7 gradients with 3-5, CDDP maximum concentration 200 μ g/ml continue to cultivate 72 hours, add 5mg/ml MTT (tetramethyl azo azoles salt, U.S. Sigma company) 20 μ l, 37 ℃, 5%CO ₂Continue to cultivate 4 hours, control clean culture medium, add 100 μ l lysates (contain 20%SDS, 50%N-N dimethyl formamide, pH 4.7), spend the night, full-automatic microplate reader is measured light absorption value (OD value) with 540nm, can ask the meansigma methods of calculating every kind of drug level light absorption value, calculates cell survival rate and suppression ratio, according to drug level and suppression ratio, use SPSS11.5 computed in software IC50 (drug level that suppresses the growth of 50% cell) and drug resistance index (RI).

Suppression ratio (inhibition rate)=[(OD contrast-OD experiment)/OD contrast] * 100%

The IC50 of the IC50/ sensitive cell line of RI=medicine-resistant cell line

Four) morphological observation

1. inverted microscope

With 5 * 10 ⁴In being seeded to ,/ml single cell suspension in 24 well culture plates of the little slide in shop, places 37 ℃, 5%CO ₂Cultivate after 72 hours in the incubator and wash 2 times with PBS, formaldehyde fixed 10 minutes, Rui Shi-Ji's nurse Sa dyeed 2 hours, and reuse PBS washes 2 times, and room temperature is dried, and observes, takes pictures under the neutral gum mounting, light microscopic.Rui Shi-Ji's nurse Sa prescription of its dyeing liquor:

Sodium hydrogen phosphate (1/15M) 6ml

Potassium dihydrogen phosphate (1/15M) 4ml

Wright's staining liquid (Sigma) 120 μ l

MAY dyeing liquor (Sigma) 120 μ l

Ji's nurse Sa dyeing liquor (Sigma) 500 μ l

2. Ultrastructural observation in the cell

(1) cell (total cellular score 〉=1 * 10 of logarithmic (log) phase growth ⁶), abandon culture medium, PBS washing 2 times;

(2) add PBS10ml, deliver to Military Medical Science Institute (No. 27, TaiPing Road, Haidian District, BeiJing) instrument detecting center Electron Microscopy Room and carry out cell section;

(3) cell grows to exponential phase, and PBS washes twice, with cytology brush cell is scraped, and centrifugal 10 minutes of 1000g, 3% glutaraldehyde (1/15M PBS pH7.4) is fixed 2 hours, 4 ℃ of following 1/15M PBS+0.19M sucrose buffer rinsing 15 minutes under 4 ℃.4 ℃ of following gradient dehydrations of ethanol (50% ethanol, 70% ethanol, 90% ethanol, 90% ethanol+90% acetone, 90% acetone, 100% acetone respectively 10 minutes), 100% acetone at room temperature dewatered 10 minutes.100% acetone: embedding medium (1: 1) room temperature was soaked into 30 minutes, and pure embedding medium soaks into and spends the night.Carry out embedding: polymerization time is 35 ℃, 12 hours: 45 ℃, and 12 hours; 60 ℃, 24 hours.ULTRACUTE/S type microtome (U.S. RMC company) carries out ultrathin section, acetic acid uranium dye liquor lucifuge dyeing 10 minutes, lead citrate dyeing 10 minutes.

(4) voltage 75kV, EM400T Electronic Speculum (Dutch Philips company) is observed, select * 8000, * 22000 electron microscope photographings.

Five) the cell colony doubling time is measured

The take the logarithm non-drug resistance and the mdr cell of trophophase, 5000 cells of every hole inoculation in 24 well culture plates, 37 ℃, 5%CO ₂Cultivate.Get 3 porocytes every day and count, observe 7d continuously.Draw growth curve, calculate population doubling time.

Six) cell cycle analysis

Non-drug resistance of trophophase of taking the logarithm and mdr cell each 1 * 10 ⁶Make single cell suspension, the centrifugal cell of collecting, cold PBS (PH7.4) washed twice, remove supernatant, adding the PBS contain 70% cold ethanol, 3% serum fixes (20 ℃) and spends the night, the centrifugal supernatant that goes of 2000g, cold PBS washed twice and with 0.5～1ml PBS resuspended (including 200 μ g/ml RNA enzyme A), behind the mixing, 37 ℃ of water-baths 30 minutes, add 400 μ l propidium iodides (concentration 50 μ g/ml, Sigma), 4 ℃ of lucifuges dyeed 30 minutes, with the dna content of 10000 cells of FACSCalibur (U.S. company BD) cells were tested by flow cytometry.

Seven) RT-PCR

1. the extraction of cell RNA: the cell of the trophophase of taking the logarithm about 5 * 10 ⁶, with 0.25% trypsinization, PBS piping and druming is eluted in the 10ml centrifuge tube, centrifugal 10 minutes of 800rpm, and PBS washes twice, and transitional cell is to new Eppendorf pipe, and is centrifugal, abandons supernatant.After adding 500 μ lTRIzol (Sigma) mixing, the piping and druming mixing adds 500 μ l TRIzol again, jolts 30 seconds, placed 5 minutes under the room temperature, add 200 μ l chloroforms, put upside down mixing 15 seconds, and at room temperature placed 2 minutes, centrifugal 15 minutes of 4 ℃ of 12000g, get the upper strata water after centrifugal, be transferred in the new Eppendorf pipe, with 500 μ l isopropanol precipitating RNA, mixing, centrifugal 10 minutes of 4 ℃ of 12000g outwell supernatant, precipitation 70% washing with alcohol, centrifugal 10 minutes of 4 ℃ of 8000g, supernatant is removed in suction, of short duration dry 15 minutes, adds the water that 20 μ l do not have the RNA enzyme.

2. reverse transcription (Japanese TaKaRa company reverse transcription test kit): in 50 μ l reaction volumes, add 7 μ l RNA, 10mM dNTP 5 μ l, 25mM magnesium chloride 10 μ l, 2.5pmol/ the oligo dT 1 μ l of μ l, 10 * RT Buffer, 5 μ l, the RNasin 0.5 μ l of 40U/ml, the AMV 1 μ l of 5U/ml, RNase Free dH ₂O 20.5 μ l, centrifugal several seconds behind the mixing, 42 ℃ of water-baths 60 minutes, 98 ℃ of 5 minutes deactivation AMV.

3.PCR reaction, reaction system (cumulative volume 20ul):

The Taq MasterMix buffer (U.S.

10ul

Invitrogen company)

Forward primer 0.5ul

Downstream primer 0.5ul

Reverse transcription product 1ul

H ₂O 8ul

Each primer (table 1) reaction condition is that 95 ℃ of pre-degeneration 2min enter circulation, 95 ℃ of degeneration 20s, and 58 ℃ of annealing 1min, 72 ℃ are extended 50s, and 35 circulations are extended 10min for back 72 ℃.1.5% agarose separates the PCR product.Electrophoresis finishes the back, agarose gel is inserted in the camera bellows of the automatic gel images analyser of JS-380 (Shanghai Peiqing Science Co., Ltd), uses the gelscan system scan.Use QCapturePro software analysis scanning result.With β-actin is confidential reference items, carries out sxemiquantitative relatively.

Eight) Western blot

1. the cracking of cell:

The take the logarithm non-drug resistance and the mdr cell of trophophase, trypsinization, centrifugal 5 minutes of 1500rpm, supernatant discarded, it is resuspended to add aseptic PBS (pH7.4), carries out cell counting, and centrifugal 5 minutes of 1500rpm abandons supernatant, washes cell twice with cold PBS, the exhaustion supernatant.About 10 ⁶Individual cell adds laemmli lysate (U.S. Bio-Rad company), and when cell lysis, other cell is in ice-water bath.After adding lysate, 99 ℃ were boiled 10 fens, and centrifugal 10 minutes of 10000g, 4 ℃ take out the back ice-water bath.After take out measuring the sample of protein concentration, per 100 μ l add 2-ME (2 mercapto ethanol) 5 μ l with remaining sample, centrifugal 10 minutes of 10000g, 4 ℃ ,-20 ℃ of preservations.

2.BCA method is measured protein concentration

Get BCA quantification of protein test kit (Pierce) A liquid, B liquid with 50: 1 (v: v) mix, get above-mentioned sample and add in the 500 μ l AB mixed liquors mixing, blank is that 2 μ l lysates join 500 μ l AB mixed liquors, 37 ℃ of water-baths 30 minutes are with the blank zeroing, at Smartspec ^TMPlus spectrophotometer (Bio-Rad) surveys the OD value of 562nm wavelength.Use Excel drawing standard curve, ask the calculation sample concentration.

3.SDS-PAGE electrophoresis

Preparation Tris-glycine electrophoretic buffer: 25mmol/L Tris, 250mmol/L glycine, 0.1%SDS.Prepare 10% separation gel 5ml: deionized water 1.9ml, 30% acrylamide solution 1.7ml, 1.5%Tris 1.3ml (pH8.8), 10%SDS 0.05ml, 10% Ammonium Persulfate 98.5 0.05ml, TEMED 0.002ml.Above-mentioned glue was in 30 minutes after coagulations.Join 5% spacer gel 2ml: deionized water 1.4ml, 30% acrylamide solution 0.33ml, 1.0%Tris 0.25ml (pH 6.8), 10%SDS 0.02ml, 10% Ammonium Persulfate 98.5 0.02ml, TEMED 0.002ml.Above-mentioned glue was in 30 minutes after coagulations.Get sample on 30 each cell protein of μ g, 80-100v, electrophoresis 2 hours.

4. electrotransfer

Preparation transfering buffering liquid: 48mM Tris HCl, 39mM glycine, 0.037%SDS, 20% methanol.Wear glove and cut two and a gel filter paper of the same size and a pvdf membrane (Pierce).Above-mentioned filter paper and filter membrane were soaked 10 minutes with transfering buffering liquid, stack by filter paper, filter membrane, gel, filter paper, attention can not have bubble.Lower right corner labelling.80v, ice-water bath electrotransfer 2 hours.

5. immunoblotting

Preparation 10 * TBST:200mMTris HCl, 1.5mM NaCl adds 0.05%Tween-20 before the use.Pvdf membrane is taken off, and after TBST shook and washes 5 minutes, sealing was 1 hour in the TBST that contains 5% defatted milk powder.TBST shakes give a baby a bath on the third day after its birth time (15 minutes), adds one of confining liquid preparation and resists, and 4 ℃ of jogs spend the night.Shake give a baby a bath on the third day after its birth time (15 minutes) with TBST, add two anti-(HRP labellings) of confining liquid preparation, jog 1 hour.TBST shakes and gives a baby a bath on the third day after its birth time.Chemical luminous substrate liquid ECL (Pierce) A, B liquid were mixed in by volume 1: 1, with pvdf membrane effect 5 minutes, in darkroom exposure colour developing.

Nine) statistical analysis

Experimental data uses the SPSS11.5 statistical software to handle, through t check carrying out statistical analysis.

(2) experimental result

One) drug resistance index

SKOV3 is (6.67 ± 2.58) μ mol/L to the IC50 of CDDP, and RI is 1.

It is external evoked to adopt heavy dose of impact induced method and low dose of intermittently revulsion that the SKOV3 cell is carried out, and lasts 16 months and obtains two kinds of medicine-resistant cell lines, and it is stable to cultivate 4 months drug resistance in no pharmaceutical culture medium.SKOV3/CDDP-P is (27.24 ± 18.60) μ mol/L to the IC50 of CDDP, and RI is 4.12 ± 2.01; SKOV3/CDDP-80 is (76.07 ± 3.85) μ mol/L to the IC50 of CDDP, and RI is 11.50 ± 3.15.The low dose of intermittently drug resistance index of revulsion is higher than heavy dose of impact induced method (P＜0.05) (Fig. 3), the easier generation drug resistance of the low dose of heavy dose of impact induced of intermittently induction ratio.

Two) cellular morphology is observed

1. under the light microscopic: SKOV3 cell and other inductive mdr cell are tied to form adherent growth, and the SKOV3 cell becomes fusiformis under the light microscopic, the growth of epithelium sample, and clear border, refractivity is good, and (Fig. 4 is a).The most of cell death in drug-induced back, cellular morphology is elongated, and obscurity boundary is not of uniform size.Wherein, the SKOV3/CDDP-80 cellular change is more obvious, and greatly cell becomes the growth of neuronal cell sample, stretches out pseudopodium, and the nuclear deformity sees more, cytoplasmic granule increase (Fig. 4 b, c).Treat that to exponential phase, cellular morphology is recovered gradually, SKOV3/CDDP-P cellular morphology and SKOV3 cell difference are not obvious, and the SKOV3/CDDP-80 cell still is pleomorphism, and obscure boundary (Fig. 4 d, e, f).

2. under the scanning electron microscope, normal SKOV3 cell becomes fusiformis, and cell surface microvilli is abundant, and is long and very thin, is evenly distributed, and nucleus is justified greatly, swells to cell surface.The equal visible cell of CDDP-P and CDDP-80 surface microvillus is more sparse, distributes and owes even.The CDDP-P metamorphosis is little, and the CDDP-80 metamorphosis is remarkable, and cell extends to both sides from karyon, and area is big, and (Fig. 5 a).Under the transmission electron microscope, visible SKOV3 cell caryoplasm ratio is inverted, and karyon is bigger, contains 1～2 kernel, and intact nuclear membrane is smooth, and chromatin becomes lumps to assemble in the nuclear, and endochylema contains a large amount of mitochondrions.CDDP-P and the big form of CDDP-80 nucleus are irregular, bizarre nucleus as seen, nuclear membrane depression obviously has nuclear bag and nuclear prominent.The chromatin skewness, mitochondrion reduces in the in bulk that condenses that has, endochylema, has a large amount of vesicle spline structures.These vesicle spline structures partly are cavitys, and part visible particle sample thing (Fig. 5 b, c).

Three) growth curve and cell colony doubling time

The 2nd day, each cell all was in demurrage, and cell number does not have obvious increase.From 2～3d, the SKOV3 cell enters exponential phase, apparently higher than SKOV3/CDDP-P and SKOV3/CDDP-80 (Fig. 6).SKOV3, SKOV3/CDDP-P and SKOV3/CDDP-80 population doubling time (GDT) are respectively 27.49 ± 4.21h, 47.26 ± 4.64h and 57.48 ± 6.17h.The GDT of SKOV3/CDDP-P and SKOV3/CDDP-80 cell is apparently higher than SKOV3 cell (P＜0.01, P＜0.001).And the growth of SKOV3/CDDP-80 cell is the slowest, has notable difference (P＜0.01) with the SKOV3/CDDP-P cell.

Four) cell cycle distribution

The G of SKOV3/CDDP-P and SKOV3/CDDP-80 ₀/ G ₁Phase all obviously prolongs (P＜0.01), S phase and G ₂/ M the phase all shortens (P＜0.05, P＜0.01).SKOV3/CDDP-80 compares with SKOV3/CDDP-P, though each phase no significant difference, G ₀/ G ₁Phase has the trend (table 2) of prolongation.

Five) expression of drug resistance related gene

The RT-PCR method is measured multidrug resistance albumen (multiple drug resistanceprotein, MDR1), multidrug-associated protein 1 (multi-drug resistanceassociated protein 1, MRP1), lung drug-resistant protein (lung resistanceprotein 1, LRP1) and glutathione s-transferase pi (glutathioneS-transferase pi, GST-pi) expression of mRNA.SKOV3 does not express MDR1, expresses MRP1, LRP1, GST-pi.The MDR1 of SKOV3/CDDP-P raises (P＜0.01), and MRP1 and LRP1 all reduce (P＜0.01), and GST-pi does not have obvious change.The MDR1 of SKOV3/CDDP-80 raises (P＜0.01), and MRP1, LRP1, GST-pi do not have obvious change (Fig. 7,8,9).The mode of inducing that identical medicine is different has different influences for the expression of drug resistant gene, and the prompting drug dose has different mechanism for the generation of drug resistance process, and the dosage that medicine is described simultaneously has certain influence for the generation of drug resistance case.

(3) conclusion

The difference of this research in order to exist between the medicine-resistant cell line of illustrating not isogeneous induction mode and setting up, for clinical research provides better drug resistance model, selecting people's ovarian serous papillary cystadenocarcinoma SKOV3 cell for use is experimental subject, CDDP is an induced drug, use heavy dose of ballistic method and low dose of intermittently revulsion to last 16 months and set up two kinds of medicine-resistant cell line-SKOV3/CDDP-P and SKOV3/CDDP-80, it is a process slowly that visible SKOV3 produces drug resistance for CDDP.Simultaneously, the drug-fast results suggest of the low dose of heavy dose of easier generation of impact induced of intermittently induction ratio, the dosage of clinical chemotherapy medicine has certain influence for the generation of drug resistance case.The medicine-resistant cell line that this experiment is set up, in 4 months conventional incubation, the drug resistance index does not change, and drug resistance is highly stable.The mode of inducing that identical medicine is different has different influences for the expression of drug resistant gene, and the prompting drug dose has different mechanism for the generation of drug resistance process.

The screening and the checking of embodiment two epithelial ovarian cancer platinum class drug resistance related proteins

(1) experimental technique

One) cell and cell culture: people's serous ovarian cancer cell line SKOV3 purchases the preclinical medicine cell centre in the Chinese Academy of Medical Sciences.SKOV3/CDDP be this chamber adopt heavy dose of cisplatin ballistic method to induce into medicine-resistant cell line (concrete abductive approach is seen first.Because heavy dose of impact induced method and clinical chemotherapy method are similar, all are object of study with SKOV3/CDDP-P in the research of back, and called after SKOV3/CDDP).People's epithelial ovarian cancerous cell line A2780, A2780/CDDP, A2780/CBP and SKOV3/CBP are provided by Li Li professor (woman's tumor section of Guangxi Medical Uneversity Cancer Hospital).All cells is adherent growth in the DMEM that contains 10% hyclone (HG) culture fluid, places 37 ℃, 5%CO ₂Cultivate in the saturated humidity incubator.

Two) drug sensitivity test: concrete experimental procedure is seen first.

Three) two dimensional gel electrophore-sis

1. the preparation of total cellular protein: treat cell culture to exponential phase, trypsinization is put in the centrifuge tube centrifugally, and cold PBS washes twice, the centrifugal supernatant that goes, collecting cell 1 * 10 ⁶Be suspended from (2M thiourea in the 50ul lysate, EDTA 1mM, 7mol/L urea, 4%CHAPS, 40mmol/L Tris, 65mmol/L DTT), the piping and druming mixing, jolt 15 seconds, 3 circulations of fast freeze-thaw, ultrasonic to transparent, add an amount of cocktail protease inhibitor (German Roche company), 20ug/ml DNase I, 5ug/ml RNaseA (Sigma), ice bath 30 minutes, 13000g, 4 ℃ are centrifugal 30 minutes, get supernatant to another Ep pipe, (Bio-Rad) measures proteinic concentration with the Bradford method, the sample packing be stored in-70 ℃ standby.

2. the first phase solid phase pH gradient isoelectric focusing electrophoresis: total cellular protein extract (1mg) fully mixes with hydrating fluid (8mol/L urea+4%CHAPS+20mmol/L DTT+0.5%IPG bufferpH3-10NL+ trace bromophenol blue); cumulative volume 350ul; add IPGstrip and hold the glue groove; (180mm * 3mm * 0.5mm) (Britain AmershamBiosciences company) goes protection to touch glue to face down with IPG immobilized ph gradient strip pH3-10; insert gently and hold in the glue groove; drive away bubble; cover one deck DryStrip Cover Fluid (Amersham Pharmacia; #17-1335-01); build and hold glue groove lid; place on the battery lead plate of IPGphor isoelectrofocusing instrument (AmershamBiosciences); aquation and focus on 20 ℃ and carry out automatically; the total voltage time is long-pending to be 6-8 ten thousand Vh; the heavy swelling 4h of aquation wherein; carry out 6h in the 30V low-voltage, pass through 500V1h then; 1000V1.5h; 5000V1h; be stabilized at last under the 8000V and carry out.

3. balance: after isoelectrofocusing finished, the IPG adhesive tape of taking out carry sample rapidly was respectively at 20ml balance liquid A (50mmol/L Tris-HCl pH=8.8+6mol/L urea+30% glycerol+2%SDS+0.3%DTT) and each balance 15 minutes among the 20ml balance liquid B (50mmol/L Tris-HClpH=8.8+6mol/L urea+30% glycerol+2%SDS+1.85% iodoacetamide+trace bromophenol blue).

4. the second perpendicular plate SDS-PAGE electrophoresis: the concentrated glue upper end that the adhesive tape of IPG after the balance is moved to the thick continuous glue of 1.5mm (13% even separation gel), and add the SDS standard protein in the outside of one end, behind the emptying bubble with 0.5% agarose sealing, the cooling of 15C recirculated water, use 40mA/2 piece glue constant current electrophoresis 40 minutes earlier, reuse 60mA/2 piece glue constant current electrophoresis arrives the glass plate lower edge until bromophenol blue and stops electrophoresis.

Four) Coomassie brilliant blue dyeing:

1. the taking-up gel slab places in the fixative (40% ethanol, 10% glacial acetic acid, 50% distilled water), jolts 30 minutes.

2. abandon fixative, place dyeing liquor (a slice R-350 (Amersham Pharmacia) is dissolved in 10% acetic acid 1600mL) heat tinting 10 minutes.

3. place destaining solution (10% glacial acetic acid) to jolt and spend the night.

Five) gel images analysis: the gel of colour developing obtains image by Imagescanner scanner (Amersham Biosciences) and Labscan5 scanning soft (AmershamBiosciences) part.Proteinic amount is defined as constituting the summation of all pixel values of this speckle.In order more accurately to reflect the variation of protein spot amount, the content of each point is expressed as relative percentage composition (%Vol), just the pixel value of a protein spot accounts for the percent of all proteins spot pixels value in the whole gel.With ImageMaster2D Platinum analysis software (Amersham Biosciences) image is carried out background reduction, spot detection, coupling, quantification and obtain analyses such as speckle displacement coordinate.All data analysiss carry out on SPSS 11.5 softwares.

Six) preparation of mass spectrum sample:

1. decolouring

Protein band in electrophoresis and the dyeing back gel is downcut with clean dissecting knife, and adhesive tape is cut into 1-2mm ³The micelle of size places the Eppendorf pipe.After in the Eppendorf pipe, adding ultra-pure water cleaning several times, with the ammonium bicarbonate (NH of the 50mM that contains 50% acetonitrile (ACN) ₄HCO ₃) destaining solution 30 μ l soak micelle.Vibrated 20 minutes, and discarded solution, repeat 2-3 the blueness to the glue and take off to the greatest extent.

2. enzymolysis

It was dewatered fully in dry 30 minutes the micelle traditional vacuum after the decolouring, volume-diminished adds 3-10 μ L trypsin solution (0.01 μ g/ μ l), places 4 ℃ of refrigerator 20-30 minutes.Take out sample from refrigerator, examine the enzyme amount in the sample, still have residue, need unnecessary enzyme liquid sucking-off is replenished 5-10 μ l 25mM NH if micelle steeps the back enzyme liquid that rises fully ₄HCO ₃Solution is as the buffer of insulation reaction.Seal film with Parafilm sample cell was sealed the back ultrasonic 1-2 minute, place 37 ℃ of water bath heat preservations to spend the night.

3. peptide extracts

Take out the sample of step 2, centrifugal sucking-off supernatant places new Eppendorf pipe (this supernatant can be taken out 2 μ l and directly do matter assisted laser desorption ion flight time mass spectrum (MALDI-TOF-MS)).

In glue, add the about 5-100 μ of 5%TFA l, just cover micelle.With seal film with ferrule after ultrasonic 1-2 minute, insulation is 1 hour in 37 ℃ of water-baths, centrifugal back sucking-off supernatant.Note micelle not being drawn onto in the rifle head or bringing out causing sample loss.

In glue, add 5% trifluoroacetic acid (TFA): 1: 1 mixed liquor 5-100 of acetonitrile μ l, with seal film with ferrule after ultrasonic 1-2 minute, insulation is 1 hour in 37 ℃ of water-baths, centrifugal back sucking-off supernatant.

Add an amount of ACN and place for a moment, treat that the micelle dehydration bleaches, draw, merge supernatant in room temperature.

4. dry

Supernatant lyophilization with above-mentioned 4 steps extraction.

Seven) peptide quality fingerprinting spectrum identification of protein: in dried peptide mixer, add 2 μ l-7 μ l 0.5%TFA, behind the mixing, getting 0.5 μ l-1 μ l solution and the saturated matrix solution of equal-volume (alpha-cyano-4-hydroxycinnamic acid (German Bruker company) is dissolved in the 50%ACN solution that contains 0.1%TFA) mixes, add to then on the rustless steel target, the dress target is measured after the drying at room temperature.On Bruker reflex III type MALDI-TOF-MS mass spectrograph (Bruker), obtain data under 20kV, the cation mode.The mass accuracy of mass spectra peak is that interior mark is proofreaied and correct with the peak of autotomying of pancreatin.

Eight) data base querying:

Search in SwissProt and NCBInr data base by Mascot software.Querying condition: the fragments of peptides quality among the peptide quality fingerprinting figure is not limit, enzyme is selected pancreatin, variable modification selects urea to methylate and Oxidation, the fragments of peptides molecular weight margin of error is controlled at ± 100ppm, each peptide allows 1 incomplete cracking site, and source of species is selected human, and ion is selected cation and monoisotopic, selecteed segment signal all should be stronger, is more than 1 times of baseline width.

Nine) quantitative PCR:

The take the logarithm cell of trophophase extracts cell total rna, and reverse transcription synthesize cDNA, carries out quantitative PCR and reacts.Primer is by Invitrogen company synthetic (seeing Table 3).The fluorescence real-time quantitative PCR system of optimizing is 10 μ l, comprises 1 μ l primer, 1 μ l template cDNA, 5 μ l DyNAmo PCR Master Mix (Finland Finnzymes company), and 3 μ l do not have RNA enzyme water.The PCR condition setting is as follows: 95 ℃ of deactivations 2 minutes, 95 ℃ of degeneration 30s, 52 ℃ of annealing 50s, 72 ℃ extend 40s, totally 35 circulations, 72 ℃ of last extensions 7 minutes after the loop ends.Use Opticon Monitor 3 software softwares (Bio-Rad) to analyze CT (Threshold cycle) value that the PCR process respectively detects sample, the method for relative quantification is used in this experiment, uses Δ Δ C _TMethod is calculated comparison.Each experiment all repeats 3 times, gets its average.

Ten) Western blot: concrete experimental procedure is seen first.

11) statistical method

Utilize the protein spots of differential expression in one factor analysis of variance and the t inspection sample, statistical analysis carries out in SPSS 11.5.

(2) experimental result

One) medicine-resistant cell line

Six kinds of cells are more stable to the drug resistance character that the IC50 and the RI of cisplatin or carboplatin sees Table 4, four kinds of mdr cells, in the incubation, detect RI and do not have obvious change in conventional culture medium.Therefore our experimental subject is stable, increases the credibility and the repeatability of experimental result.

Two) the two dimensional gel electrophore-sis collection of illustrative plates of Proliferation of Human Ovarian Cell system and medicine-resistant cell line thereof

The protein example of every kind of cell is carried out two-dimensional gel electrophoresis respectively separate, each cell sample repeats 3 clotting glue at least, examines to dye the every clotting glue in back and can detect about 1800 protein spots.A kind of matching rate of cell sample gel can reach more than 95%, and the gel matching rate is 90% between a kind of cell line and the subbreed thereof, and the gel matching rate can reach 80%～85% between the different cell line.All of each mdr cell sample are repeated the relative volume of the mutual corresponding protein spot of gels and average, expression differs and promptly is regarded as discrepancy more than 2 times.The corresponding sensitive cells sample with it of drug resistance compares, and has determined differential protein speckle relevant with platinum class drug resistance in different cell lines.These points mainly are distributed in the scope of isoelectric point, IP 5～9, molecular weight 14.0kDa～70.0kDa.

Three) peptide quality fingerprinting spectrum identification of protein

Obtained respectively by software analysis human ovarian cancer drug-resistant cell line SKOV3/CDDP, SKOV3/CBP, A2780/CDDP and A2780/CBP and its parental cell differential expression 62 protein spots (P＜0.05) (Figure 10), utilize the MALDI-TOF-MS success evaluation 57 protein spots.In order to guarantee the accuracy of matching result, the matched protein point on the different gels is carried out mass spectrum simultaneously identify that the result shows that they are identical protein.In the protein expression profile of four kinds of mdr cells, we find that every kind of mdr cell all has 12～16 species diversity marking proteins, amount to 36 kinds of protein, wherein surpass 1/3 differential protein and belong to enzyme.Study carefully its function and included the metabolism of many aspects, as energy metabolism, nucleotide metabolism, redox, cytoskeleton related protein, protein-fat-metabolism, signal transduction or the like.

Four) differential expression protein of SKOV3/CDDP and SKOV3 cell

In the drug resistance subbreed SKOV3/CDDP of SKOV3, find to have 14 protein spots differential expressions (P＜0.05).Wherein, 9 protein spots up-regulateds, 5 protein spots down-regulated expressions (table 5).In these differential expression protein points, some protein such as heat-shock protein family (point 21 and 28) have been proved relevant with drug resistance, in the drug resistance specimen up-regulated 7 times.Annexin A3 (point 25) expression raises 4 times, and the expression of villin 2 (point 1) and IDHc (point 7) has reduced by 7 times and 9 times respectively than parental cell.

Five) differential expression protein of SKOV3/CBP and SKOV3 cell

SKOV3/CBP compares with SKOV3, has 16 protein spots differential expressions (P＜0.05) (table 6).In SKOV3/CBP, some protein demonstrate the different differential expressions with SKOV3/CDDP.Stomatin (EPB72)-like 2 (point 4) reduces in SKOV3/CDDP, and in SKOV3/CBP high expressed. heat shock 70kDa albumen 1A and Heat shock protein 27 HSP27 also show the expression trend opposite with SKOV3/CDDP.The up-regulated of stathmin 1 (point 18) and phosphoglycerate mutase 1 (putting 14) four times, IDHc (spot 7) has reduced 3 times.Compare with SKOV3/CDDP, annexin A3 (point 25) has only raised 3 times.In the research in the past, the rise of annexin A1 (point 9) is relevant with drug resistance, and annexin A1 is downward modulation in SKOV3/CBP.In these 16 differential expression proteins, the intensity of protein site changes all between 2～4 times.

Six) differential expression protein of A2780/CDDP and A2780 cell

Because A2780 and SKOV3 all belong to the epithelial ovarian cancer, the protein expression collection of illustrative plates of A2780 cell is similar to SKOV3.In the tolerance cisplatin cell A2780/CDDP of A2780,15 differential expression protein points (P＜0.05) (table 7) are arranged.Wherein, the low expression of 4 protein spots is only arranged, in A2780, the low expression of annexin A3 (point 25), and the expression of annexin A3 has raise 20 times in A2780/CDDP..GSTO1-1 (point 54) and splicing factor, arginine /serine-rich 3 (putting 33) raised 5 times and 6 times respectively.

Seven) differential expression protein of A2780/CBP and A2780 cell

Though A2780/CBP and SKOV3/CBP set up under the inducing of carboplatin, they are very not identical in the expression of differential protein.In A2780/CBP, find 12 protein spots differential expressions (P＜0.05) (table 8), wherein have 5 protein spots downward modulations, and all reduce 2～3 times.Phosphoribosyltransferase (point 32) and UMP-CMPK (point 31) have raised 3 times and 4 times respectively, in SKOV3/CBP, and the slight rise of ECH1 protein (point 47) and stathmin 1 (spot 18), and in A2780/CBP, reduce.The expression of Cofilin 1 (point 34) also is opposite tendency, in A2780/CBP, significantly raises (10 times), and downward modulation in SKOV3/CBP.Yet dUTP pyrophosphatase (point 56) expresses but and all descends.

In four kinds of mdr cells differentially expressed protein separately, we find that 5 kinds of protein are in the different expression of mdr cell mean deviation (table 9) more than three kinds.Wherein, annexin A3 (Figure 11,12) and destrin express in the drug resistance specimen all and raise, wherein raise the most remarkable (3～20 times) (Figure 13) with annexin A3, NADP-dependent isocitratedehydrogenase 1 (IDHc) is all downward modulations (Figure 14) in four kinds of mdr cells.Glutathione transferase omega 1 (GSTO1-1) does not have the change except expressing in SKOV3/CBP, expresses in SKOV3/CDDP, A2780/CDDP and A2780/CBP and all raises (Figure 15).And cofilin 1 shows diametrically opposite character, and down-regulated expression in two kinds of mdr cells of SKOV3 but all raises in the mdr cell of A2780 (Figure 16).

Eight) quantitative PCR method detects the expression of mRNA

In order to verify the expression of five kinds of protein in SKOV3 and A2780 cell and their drug resistance subbreed separately, detect at rna level.Result (Figure 17) shows that SKOV3 and A2780 cell are all low expresses annexin A3, and the annexin A3 level of their cisplatin and carboplatin mdr cell all obviously raises (P＜0.01).Destrin raises (P＜0.01, P＜0.05) in SKOV3/CDDP, SKOV3/CBP and A2780/CDDP cell.Cofilin1 only raises (P＜0.05), downward modulation (P＜0.01) among the A2780/CDDP in SKOV3/CBP.And GSTO1-1 up-regulated (P＜0.01) in the mdr cell of cisplatin induction only.Except A2780/CDDP, IDHc is all downward modulations (P＜0.01, P＜0.05) in other three kinds of mdr cells.

Nine) Western blot detects the expression of annexin A3

Further four species diversity expressing protein annexin A3, destrin, cofilin 1 and GSTO1-1 are carried out western blot checking (not buying IDHc antibody).The result as can be seen, western blot result (Figure 18) and two dimensional gel electrophore-sis (2-DE) result are in full accord.Point out these five kinds of protein in the formation of drug resistance character, to play a role, and these proteinic rises or downward modulation may occur in different level (rna level or protein level or have both at the same time) in mdr cell.

(3) conclusion

In our research, four kinds of mdr cells detect the drug resistance index in incubation all do not have obvious change.Therefore our experimental subject is stable, increases the credibility and the repeatability of experimental result, for research platinum class resistance mechanism has been set up the good cell model.In the protein expression profile of four kinds of mdr cells, every kind of mdr cell all has 12～16 species diversity marking proteins, amounts to 36 kinds of protein, wherein surpasses 1/3 differential protein and belongs to enzyme.Study carefully its function and included the metabolism of many aspects, as energy metabolism, nucleotide metabolism, redox, cytoskeleton related protein, protein-fat-metabolism, signal transduction or the like.In these differential expression proteins, we have found that 5 kinds of protein all have significant change in three above samples, be respectively annexin A3, destrin, IDHc, GSTO1-1 and cofilin 1, wherein change the most remarkable (3～20 times) with annexin A3, point out these five kinds of protein in the formation of drug resistance character, to play a role, and these proteinic rises or downward modulation may occur in different level (rna level or protein level or have both at the same time) in mdr cell.

The Function Identification of embodiment three candidate's drug resistance associated protein annexin A3

Annexin A3 has carried out platinum class drug resistance correlational study, because quantitative PCR, the westen blot result of annexin A3 are all consistent with 2-DE result, and tool significantly raises trend (3～20 times), therefore selects annexin A3 as the drug resistance correlation candidate albumen that carries out functional study.

(1) experimental technique

One) structure of plasmid

1. make up the plasmid (pcDB-sense anx3 and pcDB-antisense anx3) that contains annexin A3 (anx 3) the positive antisense sequences of genes of interest

(1) design of primers: according to known people anx 3 sequences (gi:4826642) design mRNA translation district total length primer among the Genbank.Sense 5 '-gaattcCATCATGGCATCTATCTGGGTT-3 ', Antisense 5 '-gaattcGTCATCTCCACCACAGA-3 ', pcr amplification product length is 984bp, italic is a restriction enzyme site, all add restriction enzyme site EcoR I in both sides, synthetic T7 primer TAATACGACTCACTATAGGG, primer is synthetic by Invitrogen company.

(2) extract total RNA and reverse transcription concrete steps and see first

(3) pcr amplification: with cDNA is template, reaction volume 25 μ l, composition is as follows: Pfu 10 * Rxn buffer (U.S. Promega company) 2.5 μ l, 10mM dNTP 2 μ l, deionized water 19 μ l, each 0.5 μ l of anx3 upstream and downstream primer (seeing the design of primers part), pUC-anx3 plasmid 0.3 μ l, Pfu DNA polymerase (Promega) 0.2 μ l is placed into the PCR instrument, enters circulation behind 95 ℃ of degeneration 1.5min, 95 ℃ of degeneration 1min, annealed 1 minute for 50 ℃, 72 ℃ are extended 1.5min, and 35 circulations are extended 10min for back 72 ℃.

Preparation electrophoresis liquid: 0.04mol/L Tris-acetic acid, 0.001mo l/L EDTA; The sepharose electrophoresis glue that contains 0.5ug/ml EB of preparation 1.0% is got 25 μ l product and is added the comb hole, and electrophoresis is 20 minutes under the 120V voltage conditions, behind the electrophoresis gel is put into the automatic gel images analyser of JS-380, takes a picture.

(4) dna gel reclaims: according to the sky is that the agarose gel DNA of Time Technology company limited reclaims the test kit description and carries out.

1) with a clean blade single DNA band is downcut from agarose gel, excise unnecessary gel as far as possible, take by weighing its weight.

2) add 3 times of volume solution PN.

3) 50 ℃ of water-bath 10min, during continuous upset centrifuge tube, to peptization fully.

4) will go up step gained solution and add in the adsorption column, 13000 leave heart 60s, outwell the waste liquid in the collecting pipe.

5) add rinsing liquid 800 μ l PW, 13000 change, and 60s discards waste liquid.

6) add rinsing liquid 500 μ l PW, 13000 change, and 60s discards waste liquid.

7) centrifugal adsorption column is put back to collecting pipe, 13000 leave heart 2min, remove rinsing liquid as far as possible.

8) take out adsorption column and put into a clean centrifuge tube, add 20 μ l in the adsorbed film centre position and wash film buffer EB, room temperature is placed 2min, and 13000 leave heart 60s, and in the centrifugal solution that the obtains centrifugal adsorption column of add-back again, 13000 leave heart 60s.

Measure concentration: take out in the deionized water of above-mentioned solution to 99 μ of 1 μ l l,, use ultraviolet spectrophotometer to measure the OD value of 260nm, press 10D=50 μ g/ml DNA and calculate with the zeroing of 100 μ l deionized waters.The ratio of OD260/OD280 should be between 1.7-1.9.

(5) add end reaction: carry out according to the appended method description of the pGEM-T carrier of Promega company.Reaction system 25 μ l:Taq 10 * buffer 2.5 μ l, 10mM dNTP 5 μ l, 25mM Mgcl ₂5 μ l, Taq DNA polymerase (TaKaRa) 0.5 μ l, PCR product 12 μ l are placed into the PCR instrument, and 72 ℃ were reacted 30 minutes.

(6) solution reclaims

Reaction solution is reclaimed with DNA Fragment Purification Kit Ver.2.0 (TaKaRa).

1) in above-mentioned reactant liquor, adds 100 μ l DB Buffer, uniform mixing then.

2) the Spin Column in the test kit is placed on the Collection Tube.

3) solution with aforesaid operations 1 is transferred among the Spin Column, and 12000 left the heart 1 minute, outwelled the waste liquid in the collecting pipe.

4) the Rinse A with 500 μ l adds among the Spin Column, and 12000 leave heart 30s, discard waste liquid.

5) the Rinse B with 700 μ l adds among the Spin Column, and 12000 leave heart 30s, discard waste liquid.

6) repetitive operation step 5.

7) Spin Column is put into the centrifuge tube of a clean 1.5ml, add 20 μ l Elution Buffer in SpinColumn film centre position, room temperature is placed 1min, and 12000 leave 1 minute eluted dna of the heart.

(7) with the coupled reaction of T carrier: reaction system 10 μ l:10 * T ₄DNA Ligasebuffer 1 μ l, T ₄DNA Ligase (TaKaRa) 1 μ l, deionized water 2 μ l have added the PCR product 5 μ l of A tail, pGEM-T carrier (Promega) 1 μ l, mixing spends the night for rearmounted 4 ℃.

(8) preparation of competent escherichia coli cell

1) original bacteria liquid (80 ℃ of storages) is taken out 100 μ l and add in the 5ml LB bacteria culture media, 37 ℃, the 200rpm/min shaken cultivation is spent the night.

2) get on the 50 μ l step bacterium liquid and be transferred to one and contain in the 5ml LB medium centrifugal pipe, 37 ℃, 220rpm/min shaken cultivation 3 hours.Measured the growing state that the OD600 value is monitored culture every 20-30 minute, make viable count should not surpass 10 ⁸/ ml.

3) culture is transferred in aseptic, the ice-cold centrifuge tube, placed on ice 10 minutes.

4) 4 ℃, 4000rpm centrifugal 10 minutes, abandons clean supernatant.

5) with the resuspended antibacterial of calcium chloride of the 0.1M of 600 μ l pre-coolings, placed ice bath 30 minutes.

6) 4 ℃, 4000rpm centrifugal 10 minutes, abandons clean supernatant.

7) every 50ml initial incubation thing is distributed into 50 μ l portions then with the resuspended antibacterial of calcium chloride of the 0.1M of 2ml pre-cooling, puts 4 ℃ and stores use in 12-24 hour.Also can put-80 ℃ of long preservation.

(9) transformed competence colibacillus cell:

1) 200 μ l competent cells of prepared fresh place on ice, lightly cell are evenly suspended after separating ice fully.

2) add 10 μ l plasmid DNA, mixings gently.

3) place 30 minutes on ice.

4) 42 ℃ of water-bath heat shocks are 90 seconds.

5) place 2 minutes on ice.

6) add 150 μ l LB culture fluid, the recovery in 45 minutes of 37 ℃ of 100rpm/min shaken cultivation.

7) competent cell that 150 μ l have been transformed is transferred to and is contained antibiotic (Amp ⁺) the agarose culture medium on, before being coated with, add 20 μ l x-gal (20mg/ml) and 4 μ l isopropyl-β-D galactose solution (200mg/ml).Evenly coating places room temperature to be absorbed until liquid flat board.

8) plate is inverted, was cultivated 12-16 hour for 37 ℃.

After dull and stereotyped 37 ℃ of overnight incubation, visible several blue white maculas, the picking white macula joins among the 5ml LB that contains 90 μ g/ml Amp, 200rpm/min, 37 ℃ are spent the night.

(10) extraction of plasmid DNA (concrete steps are the extraction test kit description of Science and Technology Ltd.'s plasmid DNA referring to the sky)

1) with the 3ml antibacterial of incubated overnight, high speed centrifugation 1 minute (4 ℃, 4000rpm, centrifugal 10min) is thoroughly removed supernatant.

2) add 200 μ l solution P1, with rifle head or the agitator antibacterial that fully suspends.

3) add 200 μ l solution P2, gentleness turns upside down and makes the antibacterial cracking for 6-8 time, and the room temperature placement became clarification less than 5 minutes to solution.

4) add 200 μ l solution PIII, gentleness turns upside down 6-8 time, and fully mixing white precipitate can occur at this moment, and 12000rpm is 10 minutes, centrifugal.

5) supernatant is changed in the new centrifuge tube, add 200 μ l and remove endotoxin resin liquid SW (with the abundant mixing of preceding need, make resin suspend), room temperature is placed 10min, during mix and spin upside down centrifuge tube tree time.

6) gained solution and resin are changed among the Filter column CS, the centrifugal 2min of 12000rpm discards Filter column CS, collects the solution that obtains after centrifugal.

7) add 700 μ l in conjunction with liquid PB in above-mentioned solution, fully behind the mixing, add at twice among the adsorption column CB, centrifugal 30 seconds of 12000rpm outwells the waste liquid in the collecting pipe.8. add 300 μ l in conjunction with liquid PB, centrifugal 30 seconds of 12000rpm outwells the waste liquid in the collecting pipe.

8) add 700 μ l rinsing liquid PW, (please checking to have added dehydrated alcohol whether earlier before using), centrifugal 30 seconds of 12000rpm outwells waste liquid.

9) repeat to drill and do 2 times, outwell waste liquid.

10) the centrifugal 2min of 12000rpm removes rinsing liquid as far as possible.

11) take out adsorption column CB, put into a clean centrifuge tube, add 100 μ l elution buffer EB, room temperature is placed 1min, and the centrifugal 1min of 12000rpm adds the solution that obtains in the centrifugal adsorption column again, the centrifugal 1min of 12000rpm.

(12) enzyme action and the PCR of Anx3 reorganization T carrier identify

Getting bacterium liquid is the template performing PCR, reaction system 20 μ l:2 * Hot-start TaqMasterMix (sky is the Time Technology company limited) 10 μ l, each 0.5 μ l of aforementioned anx3 upstream and downstream primer, deionized water 8.5 μ l, bacterium liquid 0.5 μ l, be placed into the PCR instrument, enter circulation behind 95 ℃ of degeneration 5min, 95 ℃ of degeneration 1min annealed 1 minute for 50 ℃, 72 ℃ are extended 1.5min, and 30 circulations are extended 10min for back 72 ℃.

Select positive colony utilizes restricted enzyme EcoR I (TaKaRa) to carry out enzyme action and identifies reaction system 20 μ l:EcoR I 1 μ l, 10 * H Buffer2 μ l, DNA10 μ l, aquesterilisa 7 μ l behind the extracting plasmid.37 ℃ of water-bath 1.5h.

Enzyme action and PCR are identified all male clone, further carry out dna sequencing (Beijing AudioCodes bio tech ltd).

(13) Construction of eukaryotic

Adopt EcoR I enzyme action pcDNA3.1/myc-His (-) B plasmid (Invitrogen) (Figure 19), enzyme action system 30 μ l:EcoR I 2 μ l, 10 * H Buffer, 3 μ l, DNA24 μ l, aquesterilisa 1 μ l, 37 ℃ of water-bath 3.5h reclaim test kit (sky is the Time Technology company limited) with agarose gel DNA and reclaim product.For preventing that linearized vector carries out the dephosphorylation reaction from connecting, reaction system is as follows: linearization carrier 15 μ l, 10 * calf intestine alkaline phosphatase buffer, 2 μ l, calf intestine alkaline phosphatase (Promega) 3 μ l, 37 ℃ of effect 30min.Press DNA Fragment Purification Kit Ver.2.0 (TaKaRa) afterwards and reclaim the dephosphorylized linearized vector of purification.

Adopt EcoR I enzyme action Anx3 reorganization T carrier, enzyme action system 30 μ l:EcoR I 2 μ l, 10 * H Buffer, 3 μ l, DNA18 μ l, aquesterilisa 7 μ l, 37 ℃ of water-bath 1.5h reclaim test kit (sky is the Time Technology company limited) with agarose gel DNA and reclaim the purpose fragment.

(14) coupled reaction: reaction system 10 μ l:10 * T ₄DNA Ligase buffer1 μ l, T4 DNA Ligase (TaKaRa) 1 μ l, the dephosphorylized pcDNA3.1/myc-His of enzyme action (-) B plasmid 4 μ l, purpose fragment 4 μ l, mixing spends the night for rearmounted 16 ℃.

(15) transformed competence colibacillus cell: 10 μ l coupled reaction products add in the 200 μ l competent cells, and step is the same,

Dull and stereotyped (Amp ⁺), picking colony joins among the 5ml LB that contains 90 μ g/ml Amp, 200rpm/min, and 37 ℃ are spent the night.Enzyme action and PCR identification experiment step with recombiant plasmid.

(16) enzyme action of Anx3 recombinant eukaryon expression vector carrier and PCR identify

Getting bacterium liquid is the template performing PCR, and reaction system 20 μ l add T7, anx3 downstream primer mixture and T7 respectively, anx3 forward primer (seeing the design of primers part) mixture is identified forward and oppositely be connected that concrete steps are the same.

Select forward and reverse clone utilizes restricted enzyme EcoR I to carry out enzyme action and identifies behind extracting plasmid (extracting plasmid sees before).

Enzyme action and PCR are identified all male clone, further carry out dna sequencing.

The main flow process that makes up pcDB-sense anx3 and pcDB-antisense anx3 is seen Figure 20.

2. make up the plasmid (pcDNA3.1-anx3) that contains annexin A3 (anx 3) genes of interest justice sequence

With the pUC19-anx3 plasmid (French C é line professor Raguenes-Nicol present, I.C.G.M., U332 I.N.S.E.R.M., Paris, France) and pcDNA3.1 (+) plasmid (Invitrogen) (Figure 21) adopt EcoR I single endonuclease digestion.

20 μ l systems, 10 * K Buffer, 2 μ l

EcoR I 1μl

PUC19-anx3 or pcDNA3.1 (+) plasmid 10 μ l

Deionized water complements to 7 μ l

Effect 3h adds 2 μ l, 10 * Loading Buffer (TaKaRa) cessation reaction.Dna gel reclaims product, and linear pcDNA3.1 (+) plasmid carries out dephosphorylation to be handled, and solution product reclaims and is used for connecting.

10 μ l systems, 10 * T ₄ DNA Ligase buffer 1 μ l

T ₄ DNA Ligase(TaKaRa)1μl

Linear pEGFP-N1 plasmid 4 μ l

Purpose fragment 4 μ l

Mixing spends the night for rearmounted 16 ℃.Connect product and transform, choosing colony, amplification is identified, concrete experimental procedure is the same.

The main flow process that makes up pcDNA3.1-anx3 is seen Figure 22.

3. the plasmid (pEGFP-N1-anx3) of construction expression annexin A3 fusion rotein

To go up step pcDB-sense anx3 and pEGFP-N1 vector plasmid (U.S. Clontech company) and (Figure 23) adopt double digestion, be respectively Xho I and BamH I (TaKaRa).

20 μ l systems, 10 * K Buffer, 2 μ l

BamH I 1μl

Xho I 1μl

pcDB-sense anx3 16μl

20 μ l systems, 10 * K Buffer, 2 μ l

BamH I 1μl

Xho I 1μl

pEGFP-N1 10μl

Deionized water is supplied 20 μ l

Effect 3h adds 2 μ l, 10 * Loading Buffer cessation reaction.Dna gel reclaims product and is used for connecting.

10 μ l systems, 10 * T ₄ DNA Ligase buffer 1 μ l

T ₄ DNA Ligase(TaKaRa)1μl

Linear pEGFP-N1 plasmid 4 μ l

Purpose fragment 4 μ l

Mixing spends the night for rearmounted 16 ℃.Connect product and transform, choosing colony, amplification is identified, concrete experimental procedure is the same.

The main flow process that makes up pEGFP-N1-anx3 is seen Figure 24.

Two) cell transfecting

1. extract plasmid (Qiagen plasmid extraction kit)

(1) the LB fluid medium that 5mL is contained Apm joins in two test tubes, inserts the escherichia coli of the plasmid that contains justice and antisense gene respectively, and 37 ℃, the 200rpm/min shaken cultivation is spent the night.With the 3ml antibacterial of incubated overnight, 4 ℃, 4000rpm, centrifugal 10min thoroughly removes supernatant.

(2) add 300 μ l Buffer P1, with rifle head or the agitator antibacterial that fully suspends.

(3) add 300 μ l Buffer P2, gentleness turns upside down and makes the antibacterial cracking for 4-6 time, and the room temperature placement became clarification less than 5 minutes to solution.

(4) add the 300 μ l Buffer P3 of pre-cooling, gentleness turns upside down 4-6 time immediately, ice bath 5min.

(5) mixing once more, 4000rpm, centrifugal 10min.

(6) be ready to QIAGEN-tip20,1ml Buffer QBT is added in the pillar, allow it because of gravity spontaneous current mistake.

(7) supernatant with the 5th step adds QIAGEN-tip20, spontaneous current mistake.

(8) 1ml Buffer QC is added QIAGEN-tip20, totally 4 times.

(9), when adding QF, catch the end opening of QIAGEN-tip20, collection effluent with a clean centrifuge tube with the Buffer QF dilution DNA of 0.8ml.

(10) the 0.56ml isopropyl alcohol is joined in the step centrifuge tube 12000rpm immediately, centrifugal 30 minutes.

(11) carefully abandon clean supernatant, add 1ml 70% ethanol, 12000rpm centrifugal 10 minutes, carefully outwells ethanol, room temperature airing 5min.With 20 μ l TE (pH 8.0) dissolution precipitations.

2. transfection sensitivity and mdr cell

(1) cell dissociation of exponential phase is gone down to posterity after, with 0.5 * 10 ⁶The density of/ml is inoculated in 24 orifice plates (500 μ L), places 37 ℃, 5%CO ₂Cultivate after 24 hours in the incubator and take out, determine that cell density is 90%～95% to converge.

(2) 0.8 μ g plasmid is joined 50 μ L Opti-MEM ^Among the I Reduced Serum ((Invitrogen)), gentle mixing.

(3) mixing Lipofactamine gently before use ^TM2000 ((Invitrogen)) are then at 50 μ L Opti-MEM ^Add Lipofactamine among the I Reduced Serum ^TM20002.0 μ L, incubated at room 5min behind the mixing.

(4) after upward the step, liquid was hatched 5min, it is mixed incubated at room 20min behind the mixing with the plasmid that has diluted.

(5) cell changes the culture medium of antibiotic-free into before transfection, adds then to go up step 100 μ L mixture, mixings gently.Change conventional culture medium behind the 4-6h into.

(6) respectively after transfection 12,16,24,48,72h observes fluorescence intensity and cell transfecting situation, transfection efficiency is calculated in shooting.

3. screen the single cell clone of stably express genes of interest

In the same 1-5 step of cell transfecting step, transfection 24～48h is passaged to six orifice plates with 1: 10 ratio, adds G418 behind the 24h, and final concentration is 800 μ g/ml, mixing.Contain the G418 culture medium and screened for 3 weeks.

Microscopically utilizes paper disk method picking clone (single, isolated, about 500-1000 cellularity, cellular morphology homogeneous), is inoculated in 24 orifice plates, adopts G418 to keep concentration 200 μ g/ml in the culture medium always.

Treat that cell grows to exponential phase in 24 orifice plates, 0.25% trypsin digestion cell is seeded to 6 orifice plates and continues to keep concentration 200 μ g/ml cultivation with G418.

Treat that cell grows to exponential phase in 6 orifice plates, collecting cell, western blot are identified (concrete steps are seen experiment first), picking positive colony, freeze-stored cell.And leave and take an amount of cell and continue to cultivate, carry out subsequent experimental.

4. the chemical sproof mensuration of cell behind the stable transfection

After western blot identifies, select respectively 2～3 of the cell clonies of the highest and the no annexin A3 protein expression of annexin A3 expressing quantity respectively, conventional cell culture.Collect the cell of exponential phase, carry out the mensuration (concrete steps are seen experiment first) of IC50 and RI.

(2) result

One) structure, screening and the evaluation of positive antisense plasmid pcDB-sense anx3 and pcDB-antisense anx3

1. total RNA integrity and purity are identified:

The extraction product of RNA is at 1% agarose gel electrophoresis, and 28s, 18s, three RNA of 5s are with high-visible (Figure 25) under the ultraviolet transilluminator, by dying down by force, shows not degraded of RNA.The uv-spectrophotometric instrument is measured OD value and the highest absworption peak, OD _260nmValue is 0.626, OD _280nmBe 0.337, OD _260nm/ OD _280nmValue is 1.8562, shows that RNA purity is higher.

2.RT-PCR product agarose gel electrophoresis result: shown in Figure 26, a bright band is arranged near DNA marker1000bp, consistent with the intended purposes clip size, be 984bp purpose fragment.

3.T carrier cloning (pGEM-T-anx3) is identified: getting bacterium liquid is the template performing PCR, and as seen a bright band Figure 27 is arranged near DNA marker 1000bp, consistent with the intended purposes clip size.Select positive bacterium colony behind the T carrier cloning, utilize restricted enzyme EcoR I to carry out enzyme action.Reorganization T carrier is about 3kb, produces 984bp purpose fragment and 3kb carrier segments behind the enzyme action.Enzyme action is identified electrophoresis result such as Figure 27.After checking order, known people anx 3 sequences conform to fully among sequence and the Genbank, turn out to be the anx3 gene cDNA fragment.

4. positive antisense anx3 carrier for expression of eukaryon is identified:

Behind pcDB-sense anx3 and the pcDB-antisense anx3 recombinant plasmid transformed escherichia coli, the screening positive bacteria, getting bacterium liquid is the template performing PCR, as seen at DNA marker 1000bp place an amplified band Figure 29 is clearly arranged, consistent with the intended purposes clip size.Bacterium colony extracts plasmid DNA, and EcoR I carries out enzyme action to be identified, contains the segmental recombiant plasmid of insertion and is about 6.5kb, and enzyme action produces 984bp purpose fragment and 5.5kb carrier segments, and enzyme action the results are shown in Figure 29, and is in full accord with Theoretical Calculation.Further verify with the two-way order-checking of universal primer, behind the sequence assembly with GenBank in anx 3 gene cDNAs relatively, sequence 100% conform to (Figure 30).The result shows that anx 3 gene cDNA fragments with forward and reverse pcDNA3.1/myc-His (-) the B carrier that inserts, successfully make up positive and negative adopted carrier for expression of eukaryon pcDB-sense anx3 and pcDB-antisenseanx3 respectively.Be the nucleotide sequence of Annexin A3 below:

ATGGCATCTATCTGGGTTGGACACCGAGGAACAGTAAGAGATTATCCAGACTTTAG

CCCATCAGTGGATGCTGAAGCTATTCAGAAAGCAATCAGAGGAATTGGAACTGATGAGA

AAATGCTCATCAGCATTCTGACTGAGAGGTCAAATGCACAGCGGCAGCTGATTGTTAAG

GAATATCAAGCAGCATATGGAAAGGAGCTGAAAGATGACTTGAAGGGTGATCTCTCTGG

CCACTTTGAGCATCTCATGGTGGCCCTAGTGACTCCACCAGCAGTCTTTGATGCAAAGC

AGCTAAAGAAATCCATGAAGGGCGCGGGAACAAACGAAGATGCCTTGATTGAAATCTTA

ACTACCAGGACAAGCAGGCAAATGAAGGATATCTCTCAAGCCTATTATACAGTATACAA

GAAGAGTCTTGGAGATGACATTAGTTCCGAAACATCTGGTGACTTCCGGAAAGCTCTGT

TGACTTTGGCAGATGGCAGAAGAGATGAAAGTCTGAAAGTGGATGAGCATCTGGCCAAA

CAAGATGCCCAGATTCTCTATAAAGCTGGTGAGAACAGATGGGGCACGGATGAAGACAA

ATTCACTGAGATCCTGTGTTTAAGGAGCTTTCCTCAATTAAAACTAACATTTGATGAAT

ACAGAAATATCAGCCAAAAGGACATTGTGGACAGCATAAAAGGAGAATTATCTGGGCAT

TTTGAAGACTTACTGTTGGCCATAGTTAATTGTGTGAGGAACACGCCGGCCTTTTTAGC

CGAAAGACTGCATCGAGCCTTGAAGGGTATTGGAACTGATGAGTTTACTCTGAACCGAA

TAATGGTGTCCAGATCAGAAATTGACCTTTTGGACATTCGAACAGAGTTCAAGAAGCAT

TATGGCTATTCCCTATATTCAGCAATTAAATCGGATACTTCTGGAGACTATGAAATCAC

ACTCTTAAAAATCTGTGGTGGAGATGACTGA

(SEQ ID NO：1)

Its aminoacid sequence is seen SEQ ID NO:2

Two) structure of just plasmid pcDNA3.1-anx3, screening and evaluation

PUC19-anx3 plasmid and pcDNA3.1 (+) plasmid are adopted EcoR I single endonuclease digestion respectively.Band occurs at the 1.3kb place behind the enzyme action, conform to the 1339bp length of expection.This fragment is reclaimed the back be connected, identify that through PCR band meets purpose cDNA length, and (Figure 31 a) with linear pcDNA3.1 (+) plasmid.Enzyme action identifies that as seen containing the segmental recombiant plasmid of insertion is about 6.7kb, and EcoR I single endonuclease digestion produces 1339bp purpose fragment and 5.4kb carrier segments (Figure 31 b).Further verify with the two-way order-checking of universal primer, behind the sequence assembly with GenBank in anx 3 gene cDNAs relatively, sequence 100% conform to (Figure 32).The result shows that anx 3 gene cDNA fragments insert pcDNA3.1 (+) carrier with forward, successfully makes up just carrier for expression of eukaryon pcDNA3.1-anx3.

Three) structure of pEGFP-N1-anx3, screening and evaluation

PcDB-sense anx3 is adopted Xho I and BamH I double digestion, occur bright band at the 1kb place, be the purpose fragment of 984bp.After linear pEGFP-N1 plasmid is connected, be about 5.7kb.PCR identifies, can amplify the specific fragment (Figure 33) of 984bp.Xho I and BamH I double digestion are identified visible 984bp purpose fragment and the 4.7kb carrier segments (Figure 34) of producing.Further verify with the two-way order-checking of universal primer, behind the sequence assembly with GenBank in anx 3 gene cDNAs relatively, sequence 100% forward conform to (Figure 35).The result shows and successfully makes up just eukaryon expression plasmid pEGFP-N1-anx3.

Four) transfection efficiency

This experiment is by each cell line of method transfection of liposome-mediated plasmid DNA, respectively behind transient transfection 12,16,24,48,72h observes fluorescence intensity, finds the time point at 24h, fluorescence intensity is the strongest.Calculate transfection efficiency at microscopically, the transfection efficiency of SKOV3 cell line and mdr cell subbreed thereof is 20%-25%, and the transfection efficiency of A2780 cell line and mdr cell subbreed thereof is 45%-55%, apparently higher than SKOV3 group (Figure 36).

Five) screening of positive colony

With just annexin A3 plasmid transfection sensitive cell line SKOV3, A2780, antisense annexin A3 plasmid transfection medicine-resistant cell line SKOV3/CDDP, SKOV3/CBP, A2780/CDDP and A2780/CBP.Simultaneously all in contrast with corresponding empty plasmid.G418 screens stable clone, with undressed normal cell in contrast, in containing 800 μ g/ml G418 culture medium, cultivated about 8-9 days, the normal cell contrast is all dead, continue to be forced into 3w, individual cells has been bred the clone (Figure 37) who becomes 500-1000 cell, uses paper disk method that positive colony is chosen successively to the amplification of 24,6 orifice plates, utilizes western blot to identify the purpose clone.As shown in figure 38, compare with the normal cell without any transfection, difference is not seen in the expression of annexin A3 in the cell of transfection empty plasmid.In the cell of transfection justice plasmid, annexinA3 expresses obviously and raises, and has detected the expression less than annexin A3 in the cell of transfection antisense plasmid.Wherein, select the object of the high and minimum cell clone of expression as subsequent experimental.Table 10 is listed the name to selecting positive cell clone.

Six) the chemical sproof mensuration of cell behind the stable transfection

Carry out chemical sproof detection behind the Screening and Identification positive colony.Result's (table 11) shows, compare with the transfection empty plasmid, the drug resistance index rose about 2.0～3.7 times after sensitive cells tied up to transfection justice annexin A3 plasmid, was outstanding with the SA4 cell, and mdr cell ties up to behind the transfection antisense annexinA3 plasmid about 1.2～2.2 times of drug resistance index decreased.Wherein, most of cell is to cisplatin or significant change has all taken place the drug resistance of carboplatin after transfection.Though SBm has only descended 1.2～1.4 times to CDDP and ADC6 to the drug resistance index of CBP, has significant difference through the t check analysis.The expression of prompting annexin A3 becomes positive correlation with drug resistance, and during the annexinA3 high expressed, the cell drug resistance increases; Annexin A3 expresses when being suppressed, and the cell drug resistance weakens, and illustrates that annexin A3 and epithelial ovarian cancer are closely related to the drug-fast formation of platinum class.

(3) conclusion

Utilize technique for gene engineering with just annexin A3 plasmid transfection sensitive cell line SKOV3, A2780, antisense annexin A3 plasmid transfection medicine-resistant cell line SKOV3/CDDP, SKOV3/CBP, A2780/CDDP and A2780/CBP.G418 screens stable clone, utilizes western blot to identify the purpose clone, carries out the exponential detection of drug resistance after the amplification.The result shows, compares with the transfection empty plasmid, and the drug resistance index rose 2～4 times after sensitive cells tied up to transfection justice annexin A3 plasmid, and mdr cell ties up to behind the transfection antisense annexin A3 plasmid about 2 times of drug resistance index decreased.Presentation of results annexin A3 and epithelial ovarian cancer are closely related to platinum class drug resistance, may relate to the formation of platinum class resistance mechanism.

The research that embodiment four drug resistance associated protein annexin A3 express in the epithelial ovarian cancerous tissue

(1) experimental technique

One) ovarian cancer specimen collection: collecting ovarian cancer platinum class respectively is responsive group of main chemotherapy and chemotherapy in ovarian cancer drug resistance group patient's tumor tissue specimen.Strictly regulate inclusion criteria, coupling research sample.During year January in November, 2002 to 2005, be collected in the capable oophoroma tumor cell of BJ Union Hospital of China Concord Medical Science University of Chinese Academy of Medical Sciences department of obstetrics and gynecology and subtract the art of going out, verified by postoperative pathology is patient's specimen 42 examples of epithelial ovarian cancer.Go into the group standard:

1. the constitutional epithelial ovarian cancer of pathological diagnosis.

2. the responsive group of chemotherapy in ovarian cancer: reach clinical complete remission (CR) after subtracting go out art and standard chemotherapy through satisfied tumor cell, persistent period＞6 month.

3. chemotherapy in ovarian cancer drug resistance group: subtract to reach after go out art and the standard chemotherapy through satisfied tumor cell and alleviate (CR) fully, persistent period＜6 month; The best curative effect of chemotherapeutic period tumor is PR, SD or PD person.

Collect chemotherapy in ovarian cancer sensitive organization specimen 21 example and drug resistance tissue specimen 21 examples altogether, the paraffin embedding form is preserved, and is assisted to provide by Pathology Deparment of BJ Union Hospital.The clinical data of respective patient sees Table 12,13.

Concord Hospital's Record room is consulted the responsive and drug resistance of chemotherapy totally 42 routine patients' case history, find out specimen section in whole arts by pathological number, after the doctor of Pathology Deparment reads sheet, it is bigger to select ovarian cancer tissue, do not have downright bad and hemorrhage, based on the section of tumor epithelial cell, and seek corresponding cancerous tissue wax stone and be used for SABC.

Two) immunohistochemical staining

1. the paraffin embedding tumor tissues is carried out serial section, the about 4um of thickness.After downcutting the paraffin thin slice, in turn through 30% ethanol, 50 ℃ of water logging bubbles fully launch it for a moment.Be transferred on the microscope slide 75 ℃ of roasting sheet 45min.

2. dimethylbenzene takes off paraffin (15min * 3) in turn.Series concentration ethanol (100%, 95%, 80%) soaks a moment in turn, distilled water flushing 2 times, and PBS soaks 15-30min.

3. in advance tissue antigen is carried out the reparation of the whole bag of tricks, select the best antigen retrieval method of effect.AnnexinA3 adopts the microwave reparation after testing.

4.3% hydrogen peroxide sealing 10min.

5. add one anti-ly, wet box is put in section, hatch 75min under the room temperature, PBS flushing 5min * 3 time.

6. it is two anti-that full-automatic immunohistochemical staining instrument adds, and wet box is put in section, hatches 45min under the room temperature, and PBS washes 5min * 3 time.

7.DAB colour developing 1-5min, light microscopic control.PBS, distilled water flushing.

8. haematoxylin is redyed: soak 1min in the Lignum Sappan Soviet Union, and distilled water flushing, hydrochloride alcohol digestion is soaked 1min in the light ammonia, distilled water flushing for a moment.

9. series concentration ethanol (80%, 95%, 100%) soaks a moment in turn, and dimethylbenzene soaks a moment (* 2) in turn.

10. resinene glue mounting.

Three) read sheet, criterion and yin and yang attribute contrast

All sections are not knowing to read sheet under the situation of any clinical data by the specialist of Pathology Deparment.

Criterion: brown with cytoplasm is stained positive.Account for the percentage ratio of whole tumor cells according to painted tumor cell,＜5% is (-), and 5～25% is (+), and 25～50% is (++), 50%～75% is (+++),＞75% be (++ ++), 10 visuals field of picked at random, meansigma methods is as final result.

As positive control, positive position is a cytoplasm to positive control: annexinA3 with hepatocyte.

Negative control: replace one with the rabbit anteserum before the immunity and resist.

Four) statistical analysis

Use SPSS11.5 software to carry out following statistical analysis:

Adopt the rank test evaluation chemotherapy sensitivity of ranked data and drug resistance patient's annexin A3 expression whether to have significant difference.

(2) result

Responsive 50.29 years old mean age of group of chemotherapy in ovarian cancer, 55.29 years old chemotherapy resistance group mean age, age no difference of science of statistics (P=0.265) between two groups.Other no difference of science of statistics of ovarian cancer phase (P=0.141) between two groups.

Annexin A3 mainly expresses in cytoplasm, and part is expressed in nucleus, sees Figure 39.Adopt the responsive group of rank test comparison chemotherapy of ranked data and drug resistance group patient's statistical result to show, U value=139, P value=0.035＜0.05, illustrate between chemotherapy sensitivity person and drug resistance person's the annexinA3 expression and have significant difference, chemotherapy resistance person's annexin A3 expression is higher than responsive person, see Table 14,15.Clinical effectiveness explanation annexin A3 and epithelial ovarian cancer are closely related to the drug-fast formation of platinum class.

(3) conclusion

By ovarian cancer tissue's immunohistochemical staining research to responsive patient of 21 routine chemotherapy and 21 routine drug resistance patients, the result shows, two groups annexin A3 expresses and has significant difference (P=0.035), prompting annexin A3 is a kind of platinum class drug resistance associated protein, be expected to become the label of prediction platinum class drug resistance and ovarian cancer prognosis, and may become the new target drone that reverses clinical drug-resistant.

Table 1.RT-PCR primer, product length, annealing temperature

Title	Sequence	Product (bp)	Annealing temperature (℃)
				β-actin	ACACTGTGCCCATCTACGAGG AGGGGCCGGACTCGTCATACT	621	58
MDR-1	CCCATCATTGCAATAGCAGG GTTCAAACTTCTGCTCCTGA	157	58
				MRP-1	ACCAAGACGTATCAGGTGGC CTGTCAGGTTCCAGCTCCTC	428	58
LRP-1	ACAACTACTGCGTGATTCTCG GGTCTTGACATCCTGCACATA	350	58
				GST-pi	GGTGGTGACCGTGGAGA CTCATGGATCAGCAGCAAG	397	58

The cell cycle distribution of table 2.SKOV3 and mdr cell

^*P＜0.05, ^*Compare with SKOV3 in P＜0.01

Cell cycle	SKOV3	SKOV3/CDDP-P	SKOV3/CDDP-80
				G 0/G 1(％)	46.15±3.26	60.74±2.36 **	65.41±3.88 **
S(％)	40.30±2.68	27.76±1.69 *	26.74±1.93 **
				G 2/M(％)	13.55±0.59	11.50±0.70 *	7.85±1.57 *

The primer sequence of table 3. real-time quantitative PCR, fragment length and annealing temperature

Title	Sequence	Product (bp)	Annealing temperature (℃)	SEQ ID NO：
					annexin A3	TGAAGGGTATTGGAACTGATG TGAGAAGAAGTAAGGTGGAGC	254	52	3 4
destrin	GTAAATGCTCCACACCAGAAG GCATCATACAAAGCATAGCGA	199	52	5 6
					cofilin 1	TATGAGACCAAGGAGAGCAAG CTTGACCTCCTCGTAGCAGTT	148	52	7 8
GSTO1-1	AAGCATACCCAGGGAAGAAGC TGCCATCCACAGTTTCAGTTT	334	52	9 10
					IDHc	AGAGCAAAGCTTGATAACAAT GAAAAATGTAAACCTGTAGAC	284	52	11 12
beta-actin	AAACTACCTTCAACTCCATCA AACTAAGTCATAGTCCGCCTA	319	52	13 14

The IC50 of six kinds of cell lines of table 4. and RI value, "-": the IC50 value is not surveyed

Cell line	IC50(μmol/L)		RI
				CDDP	CBP
	SKOV3	6.67±2.58				80.79±10.82	1.00
SKOV3/CDDP			27.24±8.60	-	4.12
	SKOV3/CBP	-				242.40±20.36	3.00
A2780			1.95±0.69	50.26±5.38	1.00
	A2780/CDDP	6.83±1.41				-	3.50
A2780/CBP			-	175.90±15.27	3.50

The differential expression protein of table 5.SKOV3/CDDP and SKOV3 cell

Sequence number	Protein name	Protein sequence number	Isoelectric point, IP		Molecular weight of albumen (Da)		The peptide section		Coverage rate (%)	The albumen scoring	Express
												Theoretical value	Observed value	Theoretical value	Observed value	Coupling	Amount to
			01	Villin 2	gi|46249758	5.94	6.48	69199										75258	47	69	60	328	↓
04	Stomatin(EPB72)-like 2	gi|7305503							6.88	5.50	38510	43203	19	26	53	177	↓
			07	NADP-dependent isocitrate Dehydrogenase(IDHc)	gi|3641398	6.34	6.89	46659										44484	25	41	63	321	↓
12	Annexin A4	gi|1703319							5.84	5.94	35860	33421	21	38	58	145	↑
			16	ATP synthase，H+transporting， mitochondrial F0 complex， subunit d isoform a	gi|5453559	5.21	5.19	18480										24953	10	17	72	123	↑
17	Activated RNA polymerase II transcription cofactor 4	gi|19923784							9.6	5.21	14356	18564	10	24	55	137	↑
			21	Heat shock 70kDa protein 1A	gi|5123454	5.48	5.56	69995										66358	32	56	60	251	↑
25	Annexin A3	gi|47115233							5.76	5.76	36452	35643	19	36	55	238	↑
			26	Proteasome(prosome，macropain) subunit，alpha type，1	gi|30582133	6.15	6.65	29579										31958	16	55	51	101	↓
27	Prohibitin	gi|46360168							5.57	5.62	29802	29657	14	46	67	203	↑
			28	Heat shock protein 27	gi|662841	7.83	5.71	22313										26385	16	57	73	221	↑
34	Cofilin 1(non-muscle)	gi|5031635							8.22	6.57	18491	18698	7	20	46	113	↓
			54	Glutathione-S-transferase omega 1	gi|4758484	6.23	6.51	27548										33568	11	35	39	84	↑
67	Destrin	gi|5802966							8.84	6.90	18493	19201	4	6	47	65	↑

The differential expression protein of table 6.SKOV3/CBP and SKOV3 cell

Sequence number	Protein name	Protein sequence number	Isoelectric point, IP		Molecular weight of albumen (Da)		The peptide section		Coverage rate (%)	The albumen scoring	Express
												Theoretical value	Observed value	Theoretical value	Observed value	Coupling	Amount to
			04	Stomatin(EPB72)-like 2	gi|7305503	6.88	5.50	38510										43203	19	26	53	177	↑
07	NADP-dependent isocitrate dehydrogenase(IDHc)	gi|3641398							6.34	6.89	46659	44484	25	41	63	321	↓
			09	Annexin Al	gi|54696696	6.57	6.68	38690										39621	22	34	63	228	↓
11	Unnamed protein product	gi|7022776							8.99	5.50	21244	33852	15	20	35	95	↓
			13	Lactamase，beta 2	gi|7705793	6.32	6.83	32785										32901	8	33	34	68	↓
14	Phosphoglycerate mutase 1	gi|38566176							6.67	6.69	28802	29587	13	30	48	252	↑
			15	Prosome beta-subunit； HSBpros26	gi|551547	5.70	5.74	25893										28356	11	17	48	108	↑
18	Stathmin 1	gi|15680064							5.76	5.49	17326	19068	9	14	51	114	↑
			19	Fatty acid binding protein5	gi|30583737	6.60	6.47	15155										16234	15	30	68	126	↓
21	Heat shock 70kDa protein 1A	gi|5123454							5.48	5.56	69995	66358	32	56	60	251	↓
			25	Annexin A3	gi|47115233	5.76	5.76	36452										35643	19	36	55	238	↑
28	Heat shock protein 27	gi|662841							7.83	5.72	22313	28985	16	57	73	221	↓
			34	Cofilin 1(non-muscle)	gi|5031635	8.22	6.57	18491										18698	7	20	46	113	↓
40	Peroxiredoxin 1	gi|55959887							8.27	8.06	18964	25487	24	57	87	262	↑
			47	ECH1 protein	gi|16924265	8.47	6.49	35735										33069	5	7	24	69	↑
67	Destrin	gi|5802966							8.84	6.90	18493	19201	4	6	47	65	↑

The differential expression protein of table 7.A2780/CDDP and A2780 cell

Sequence number	Protein name	Protein sequence number	Isoelectric point, IP		Molecular weight of albumen (Da)		The peptide section		Coverage rate (%)	The albumen scoring	Express
												Theoretical value	Observed value	Theoretical value	Observed value	Coupling	Amount to
			07	NADP-dependent isocitrate dehydrogenase(IDHc)	gi|3641398	6.34	6.89	46659										44484	25	41	63	321	↓
08	Aldehyde Reductase	gi|1633300							6.34	6.78	36419	40188	18	29	53	188	↑
			10	Aldo-keto reductase family 1， member B1	gi|13529257	6.6	6.90	35801										39018	11	23	25	158	↑
25	Annexin A3	gi|47115233							5.76	5.76	36452	35643	19	36	55	238	↑
			27	Prohibitin	gi|46360168	5.57	5.62	29802										29657	14	46	67	203	↓
33	Splicing factor，arginine /serine-rich 3	gi|56417681							10.12	6.19	14194	24015	8	26	54	124	↑
			34	Cofilin 1(non-muscle)	gi|5031635	8.22	6.57	18491										18698	7	20	46	113	↑
51	Lactate dehydrogenase B	gi|4557032							5.71	5.92	36615	39120	12	14	24	99	↑
			54	Glutathione-S-transferase omega 1	gi|4758484	6.23	6.51	27548										33568	11	35	39	84	↑
55	Peroxiredoxin 6	gi|4758638							6.00	6.17	25019	27933	10	14	47	103	↑
			56	dUTP pyrophosphatase	gi|4503423	6.15	5.75	17737										21532	5	7	48	81	↓
63	Purine nucleoside phosphorylase	gi|4557801							6.45	6.70	32127	32085	21	31	69	199	↑
			67	Destrin	gi|5802966	8.84	6.90	18493										19201	4	6	47	65	↑
68	Triosephosphate isomerase 1	gi|17389815							6.45	6.48	26625	28954	9	11	47	138	↓
			81	T-complex protein 1，gamma subunit(TCP-1-gamma) (CCT-gamma)	gi|20455521	6.10	6.47	60364										65539	31	43	47	242	↑

The differential expression protein of table 8.A2780/CBP and A2780 cell

Sequence number	Protein name	Protein sequence number	Isoelectric point, IP		Molecular weight of albumen (Da)		The peptide section		Coverage rate (%)	The albumen scoring	Express
												Theoretical value	Observed value	Theoretical value	Observed value	Coupling	Amount to
			07	NADP-dependent isocitrate dehydrogenase(IDHc)	gi|3641398	6.34	6.89	46659										44484	25	41	63	321	↓
18	Stathmin 1	gi|15680064							5.76	5.49	17326	19068	9	14	51	114	↓
			25	Annexin A3	gi|47115233	5.76	5.76	36452										35643	19	36	55	238	↑
31	UMP-CMPK	gi|33150592							5.44	5.64	22208	26694	11	29	55	147	↑
			32	Adenine phosphoribosyltransferase	gi|31415697	5.78	5.56	19595										24363	10	26	72	151	↑
34	Cofilin 1(non-muscle)	gi|5031635							8.22	6.57	18491	18698	7	20	46	113	↑
			47	ECH protein 1	gi|16924265	8.47	6.49	35735										33069	5	7	24	69	↓
54	Glutathione-S-transferase omega 1	gi|4758484							6.23	6.51	27548	33568	11	35	39	84	↑
			56	dUTP pyrophospha tase	gi|4503423	6.15	5.75	17737										21532	5	7	48	81	↓
67	Destrin	gi|5802966							8.84	6.90	18493	19201	4	6	47	65	↑
			82	J-type co-chaperone HSC20	gi|41388876	7.59	6.26	27405										30583	7	14	33	71	↓
83	KIAA0158	gi|40788885							6.05	6.57	42120	43307	15	36	46	110	↑

The total differential expression protein of mdr cell more than three kinds that table 9.MALDI-TOF-MS identifies

Protein name	Protein sequence number	Isoelectric point, IP		Molecular weight of albumen (Da)		The peptide section		Coverage rate (%)	The albumen scoring	The differential expression figure place
											Theoretical value	Observed value	Theoretical value	Observed value	Coupling	Amount to
		IDHc	gi|3641398	6.34	6.89	46659	44484										25	41	63	321	2～9
Annexin A3	gi|47115233							5.76	5.76	36452	35643	19	36	55	238	3～20
		Cofilin 1	gi|5031635	8.22	6.57	18491	18698										7	20	46	113	2～10
GSTO1-1	gi|4758484							6.23	6.51	27548	33568	11	35	39	84	2～5
		Destrin	gi|5802966	8.84	6.90	18493	19201										4	6	47	65	2～3

The purpose clone's who selects after table 10. couple western blot identifies name

Cell line	The transfection plasmid	Name	Cell line	The transfection plasmid	Name
						SKOV3	pcDNA3.1(+)	Sm	A2780	pcDNA3.1(+)	Am
SKOV3	pcDNA3.1-anx3	SA4	A2780	pcDNA3.1-anx3	AA4
						SKOV3/CDDP	pcDNA3.1(+)	SDm	A2780/CDDP	pcDNA3.1(+)	ADm
SKOV3/CDDP	pcDB-antisense anx3	SDR6	A2780/CDDP	pcDB-antisense anx3	ADR6
						SKOV3/CBP	pcDNA3.1(+)	SBm	A2780/CBP	pcDNA3.1(+)	ABm
SKOV3/CBP	pcDB-antisense anx3	SBR6	A2780/CBP	pcDB-antisense anx3	ABR6

Purpose is cloned chemical sproof detection behind table 11. stable transfection

Cell line	IC50 (cisplatin)		IC50 (carboplatin)
					IC50(μM)	RI	IC50(μM)	RI
	Sm	6.12±1.67	1.00	87.73±20.89					1.00
SA4					22.83±3.74**	3.73	213.16±28.4**	2.43
	SDm	16.56±3.12	1.00	242.73±19.11					1.00
SDR6					7.38±2.23**	0.45	122.59±15.71**	0.51
	SBm	10.98±2.44	1.00	169.66±16.93					1.00
SBR6					9.13±1.83*	0.83	102.28±13.17**	0.60
	Am	1.81±0.45	1.00	60.42±11.73					1.00
AA4					3.69±1.07*	2.04	107.79±13.57**	1.78
	ADm	4.45±1.15	1.00	125.28±19.18					1.00
ADR6					2.34±0.62*	0.53	91.81±13.93*	0.73
	ABm	9.79±2.01	1.00	135.7±15.37					1.00
ABR6					6.02±2.18*	0.61	62.13±10.54**	0.46

The responsive patient clinical data of the routine chemotherapy in ovarian cancer of table 12.21

Numbering	Age	Types of organization	By stages
				S1	57	Clear cell carcinoma	IIIc
S2	63	Clear cell carcinoma	IIIc
				S3
	56	The slurry breast carcinoma	IIIc
				S4	50	The slurry breast carcinoma	IIc
S5
		40	The slurry breast carcinoma	IIIc
S6					49	The slurry breast carcinoma	IIIc
	S7
		42	The slurry breast carcinoma	IIIc
	S8				46	The slurry breast carcinoma	IIIc
S9		53	The slurry breast carcinoma	IIIc
	S10				67	The slurry breast carcinoma	IIIb
S11		57	The slurry breast carcinoma	IIIc
	S12				49	The slurry breast carcinoma	IV
S13		48	The slurry breast carcinoma	IIa
	S14				47	The slurry breast is low	IIIc
S15		62	Inner membrance sample cancer	IIIc
	S16				39	Inner membrance sample cancer	IIc
S17		44	Inner membrance sample cancer	IIIc
	S18				49	Inner membrance sample cancer	IIc
S19		58	Inner membrance sample cancer	IIIc
	S20
		42	Inner membrance sample cancer	IIIc
	S21				38	The mucus cancer	IIIc

The routine chemotherapy in ovarian cancer drug resistance of table 13.21 patient clinical data

Numbering	Age	Types of organization	By stages
				R1	64	Clear cell carcinoma	IIIc
R2
		61	Clear cell carcinoma	IIIc
R3					51	Clear cell carcinoma	IV
	R4	63	The slurry breast carcinoma	IIIc
R5					48	The slurry breast carcinoma	IIIc
	R6
		52	The slurry breast carcinoma	IIIc
	R7
		52	The slurry breast carcinoma	IIc
	R8
		52	The slurry breast carcinoma	IIIc
	R9
		61	The slurry breast carcinoma	IIIc
	R10				54	The slurry breast carcinoma	IIIc
R11		65	The slurry breast carcinoma	IIIc
	R12				75	The slurry breast carcinoma	IIIc
R13		51	The slurry breast carcinoma	IIIc
	R14
		42	The slurry breast carcinoma	IIIb
	R15				51	The slurry breast carcinoma	IIIc
R16		59	Transitional cell carcinoma	IIIc
	R17
		52	Transitional cell carcinoma	IIIc
	R18				55	Transitional cell carcinoma	IIIc
R19		54	Inner membrance sample cancer	IIIc
	R20				53	Inner membrance sample cancer	IIIc
R21
		52	The mucus cancer	IIIc

The coloration result of routine chemotherapy in ovarian cancer sensitivity of table 14.42 and drug resistance tissue specimen

Numbering	Annexin A3	Numbering	Annexin A3
				S1
	4+	R1	4+
				S2	3+	R2	4+
S3	3+	R3	3+
				S4	2+	R4	3+
S5	2+	R5	3+
				S6	2+	R6	3+
S7	2+	R7	3+
				S8	1+	R8	2+
S9	1+	R9	2+
				S10	1+	R10	2+
S11	1+	R11	2+
				S12	1+	R12	2+
S13	1+	R13	2+
				S14	1+	R14	1+
S15	-	R15	1+
				S16	-	R16	1+
S17	-	R17	1+
				S18	-	R18	1+
S19	-	R19	1+
				S20	-	R20	-
S21	-	R21	-

The expression of results of table 15.Annexin A3 in chemotherapy in ovarian cancer sensitivity and drug resistance tissue relatively

Annexin A3 expression	Responsive (example)	Drug resistance (example)
			-	7	2
1+	7	6
			2+	4	6
3+	2	5
			4+	1	2
Amount to	21	21

Sequence table

＜110〉Chinese Academy of Medical Sciences Beijing Union Medical College Hospital

＜120〉dependency of the platinum-based chemotherapy drug resistance of Annexin A3 and cancer

<130>IDC060070

<160>14

<170>PatentIn version 3.2

<210>1

<211>972

<212>DNA

＜213〉people

<220>

<221>CDS

<222>(1)..(972)

<400>1

atg gca tct atc tgg gtt gga cac cga gga aca gta aga gat tat cca 48

Met Ala Ser Ile Trp Val Gly His Arg Gly Thr Val Arg Asp Tyr Pro

1 5 10 15

gac ttt agc cca tca gtg gat gct gaa gct att cag aaa gca atc aga 96

Asp Phe Ser Pro Ser Val Asp Ala Glu Ala Ile Gln Lys Ala Ile Arg

20 25 30

gga att gga act gat gag aaa atg ctc atc agc att ctg act gag agg 144

Gly Ile Gly Thr Asp Glu Lys Met Leu Ile Ser Ile Leu Thr Glu Arg

35 40 45

tca aat gca cag cgg cag ctg att gtt aag gaa tat caa gca gca tat 192

Ser Asn Ala Gln Arg Gln Leu Ile Val Lys Glu Tyr Gln Ala Ala Tyr

50 55 60

gga aag gag ctg aaa gat gac ttg aag ggt gat ctc tct ggc cac ttt 240

Gly Lys Glu Leu Lys Asp Asp Leu Lys Gly Asp Leu Ser Gly His Phe

65 70 75 80

gag cat ctc atg gtg gcc cta gtg act cca cca gca gtc ttt gat gca 288

Glu His Leu Met Val Ala Leu Val Thr Pro Pro Ala Val Phe Asp Ala

85 90 95

aag cag cta aag aaa tcc atg aag ggc gcg gga aca aac gaa gat gcc 336

Lys Gln Leu Lys Lys Ser Met Lys Gly Ala Gly Thr Asn Glu Asp Ala

100 105 110

ttg att gaa atc tta act acc agg aca agc agg caa atg aag gat atc 384

Leu Ile Glu Ile Leu Thr Thr Arg Thr Ser Arg Gln Met Lys Asp Ile

115 120 125

tct caa gcc tat tat aca gta tac aag aag agt ctt gga gat gac att 432

Ser Gln Ala Tyr Tyr Thr Val Tyr Lys Lys Ser Leu Gly Asp Asp Ile

130 135 140

agt tcc gaa aca tct ggt gac ttc cgg aaa gct ctg ttg act ttg gca 480

Ser Ser Glu Thr Ser Gly Asp Phe Arg Lys Ala Leu Leu Thr Leu Ala

145 150 155 160

gat ggc aga aga gat gaa agt ctg aaa gtg gat gag cat ctg gcc aaa 528

Asp Gly Arg Arg Asp Glu Ser Leu Lys Val Asp Glu His Leu Ala Lys

165 170 175

caa gat gcc cag att ctc tat aaa gct ggt gag aac aga tgg ggc acg 576

Gln Asp Ala Gln Ile Leu Tyr Lys Ala Gly Glu Asn Arg Trp Gly Thr

180 185 190

gat gaa gac aaa ttc act gag atc ctg tgt tta agg agc ttt cct caa 624

Asp Glu Asp Lys Phe Thr Glu Ile Leu Cys Leu Arg Ser Phe Pro Gln

195 200 205

tta aaa cta aca ttt gat gaa tac aga aat atc agc caa aag gac att 672

Leu Lys Leu Thr Phe Asp Glu Tyr Arg Asn Ile Ser Gln Lys Asp Ile

210 215 220

gtg gac agc ata aaa gga gaa tta tct ggg cat ttt gaa gac tta ctg 720

Val Asp Ser Ile Lys Gly Glu Leu Ser Gly His Phe Glu Asp Leu Leu

225 230 235 240

ttg gcc ata gtt aat tgt gtg agg aac acg ccg gcc ttt tta gcc gaa 768

Leu Ala Ile Val Asn Cys Val Arg Asn Thr Pro Ala Phe Leu Ala Glu

245 250 255

aga ctg cat cga gcc ttg aag ggt att gga act gat gag ttt act ctg 816

Arg Leu His Arg Ala Leu Lys Gly Ile Gly Thr Asp Glu Phe Thr Leu

260 265 270

aac cga ata atg gtg tcc aga tca gaa att gac ctt ttg gac att cga 864

Asn Arg Ile Met Val Ser Arg Ser Glu Ile Asp Leu Leu Asp Ile Arg

275 280 285

aca gag ttc aag aag cat tat ggc tat tcc cta tat tca gca att aaa 912

Thr Glu Phe Lys Lys His Tyr Gly Tyr Ser Leu Tyr Ser Ala Ile Lys

290 295 300

tcg gat act tct gga gac tat gaa atc aca ctc tta aaa atc tgt ggt 960

Ser Asp Thr Ser Gly Asp Tyr Glu Ile Thr Leu Leu Lys Ile Cys Gly

305 310 315 320

gga gat gac tga 972

Gly Asp Asp

<210>2

<211>323

<212>PRT

＜213〉people

<400>2

Met Ala Ser Ile Trp Val Gly His Arg Gly Thr Val Arg Asp Tyr Pro

1 5 10 15

Asp Phe Ser Pro Ser Val Asp Ala Glu Ala Ile Gln Lys Ala Ile Arg

20 25 30

Gly Ile Gly Thr Asp Glu Lys Met Leu Ile Ser Ile Leu Thr Glu Arg

35 40 45

Ser Asn Ala Gln Arg Gln Leu Ile Val Lys Glu Tyr Gln Ala Ala Tyr

50 55 60

Gly Lys Glu Leu Lys Asp Asp Leu Lys Gly Asp Leu Ser Gly His Phe

65 70 75 80

Glu His Leu Met Val Ala Leu Val Thr Pro Pro Ala Val Phe Asp Ala

85 90 95

Lys Gln Leu Lys Lys Ser Met Lys Gly Ala Gly Thr Asn Glu Asp Ala

100 105 110

Leu Ile Glu Ile Leu Thr Thr Arg Thr Ser Arg Gln Met Lys Asp Ile

115 120 125

Ser Gln Ala Tyr Tyr Thr Val Tyr Lys Lys Ser Leu Gly Asp Asp Ile

130 135 140

Ser Ser Glu Thr Ser Gly Asp Phe Arg Lys Ala Leu Leu Thr Leu Ala

145 150 155 160

Asp Gly Arg Arg Asp Glu Ser Leu Lys Val Asp Glu His Leu Ala Lys

165 170 175

Gln Asp Ala Gln Ile Leu Tyr Lys Ala Gly Glu Asn Arg Trp Gly Thr

180 185 190

Asp Glu Asp Lys Phe Thr Glu Ile Leu Cys Leu Arg Ser Phe Pro Gln

195 200 205

Leu Lys Leu Thr Phe Asp Glu Tyr Arg Asn Ile Ser Gln Lys Asp Ile

210 215 220

Val Asp Ser Ile Lys Gly Glu Leu Ser Gly His Phe Glu Asp Leu Leu

225 230 235 240

Leu Ala Ile Val Asn Cys Val Arg Asn Thr Pro Ala Phe Leu Ala Glu

245 250 255

Arg Leu His Arg Ala Leu Lys Gly Ile Gly Thr Asp Glu Phe Thr Leu

260 265 270

Asn Arg Ile Met Val Ser Arg Ser Glu Ile Asp Leu Leu Asp Ile Arg

275 280 285

Thr Glu Phe Lys Lys His Tyr Gly Tyr Ser Leu Tyr Ser Ala Ile Lys

290 295 300

Ser Asp Thr Ser Gly Asp Tyr Glu Ile Thr Leu Leu Lys Ile Cys Gly

305 310 315 320

Gly Asp Asp

<210>3

<211>21

<212>DNA

＜213〉primer

<400>3

tgaagggtat tggaactgat g 21

<210>4

<211>21

<212>DNA

＜213〉primer

<400>4

tgagaagaag taaggtggag c 21

<210>5

<211>21

<212>DNA

＜213〉primer

<400>5

gtaaatgctc cacaccagaa g 21

<210>6

<211>21

<212>DNA

＜213〉primer

<400>6

gcatcataca aagcatagcg a 21

<210>7

<211>21

<212>DNA

＜213〉primer

<400>7

tatgagacca aggagagcaa g 21

<210>8

<211>21

<212>DNA

＜213〉primer

<400>8

cttgacctcc tcgtagcagt t 21

<210>9

<211>21

<212>DNA

＜213〉primer

<400>9

aagcataccc agggaagaag c 21

<210>10

<211>21

<212>DNA

＜213〉primer

<400>10

tgccatccac agtttcagtt t 21

<210>11

<211>21

<212>DNA

＜213〉primer

<400>11

agagcaaagc ttgataacaa t 21

<210>12

<211>21

<212>DNA

＜213〉primer

<400>12

gaaaaatgta aacctgtaga c 21

<210>13

<211>21

<212>DNA

＜213〉primer

<400>13

aaactacctt caactccatc a 21

<210>14

<211>21

<212>DNA

＜213〉primer

<400>14

aactaagtca tagtccgcct a 21

Claims (26)

1. regulate the method for the platinum-based chemotherapy drug resistance of cancer, comprise the expression that changes annexin A3 in the cancer cell, wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, and described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably.

2. the method for claim 1, it is used for the drug resistance of external adjusting cancerous cell or is used for regulating in the body cancer patient's drug resistance.

3. the method for claim 1, by improving annexin A3 expression raising toleration of cancerous cell in the cancerous cell to the platinum-based chemotherapy medicine, preferably, the annexin A3 that improves in the cell by expression annexin A3 gene in cancerous cell expresses, more preferably wherein by using the plasmid of expressing just annexin A3 gene to improve the content of the annexinA3 in the described cell.

4. can improve the purposes of medicament in the medicine of the platinum-based chemotherapy drug resistance of preparation raising cancer that the annexin A3 in the cancerous cell expresses, wherein preferably described medicament is selected from: coding annexin A3 proteic polynucleotide, comprise the DNA construct or the expression vector of the proteic polynucleotide of coding annexin A3, wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably.。

5. the method for claim 1, by the expression reduction of the annexin A3 in minimizing and/or the anticancer toleration of cancer to the platinum-based chemotherapy medicine, preferably, antisensenucleic acids by expressing annexin A3 in cancerous cell and/or the ribozyme that is specific to annexin A3 reduce and/or the annexin A3 that suppresses in the cell expresses, again the content that reduces the annexin A3 in the cell of DNA construct or the expression vector by use antisence annexin A3 wherein preferably.

6. suppress the antisense nucleotide that annexin A3 expresses.

7. the antisense nucleotide of claim 6, it comprises can specific bond annexin A3 polynucleotide sequence or all or part of nucleotide sequence of any sequence of its complementary series, preferably described antisense nucleotide contains one or more part complementation with annexin A3 polynucleotide, more preferably complementary basically, even more preferably complete complementary sequence area, more preferably, described antisense nucleotide comprises and the complete complementary DNA sequence of total length annexin A3 polynucleotide, preferably, described antisense nucleotide is DNA or RNA or its derivant, most preferably, described antisense nucleotide is included in the expression plasmid that can express it, in the preferred eukaryon expression plasmid.

8. the ribozyme of special cutting annexin A3mRNA.

9. the ribozyme of claim 8, it has the specific substrate binding site with one or more annexin A3 RNA regional complementarity, and it is in this substrate binding site or have on every side and give this molecule RNA the nucleotide sequence of cleavage activity, and preferably described ribozyme is selected from: hammerhead ribozyme, hair clip type ribozyme, hepatitis D virus type ribozyme, Group I Introns type ribozyme or RNasePRNA type ribozyme or neurospora VS RNA type ribozyme.

10. can reduce and/or anticancer in the annexin A3 medicament of expressing reduce purposes in the medicine of platinum-based chemotherapy drug resistance of cancer in preparation, wherein said pharmacy optimization is selected from: claim 6 or 7 antisense nucleotide and the ribozyme of claim 8 or 9, wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably.

11. the method by claim 1 has changed the cancer cell to the toleration of platinum-based chemotherapy medicine, preferably, described cell comprises the expression vector of expressing just annexin A3 or antisense annexinA3, preferably, described carrier is a plasmid, wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, and described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably.

12. a screening can change the method for cancer to the chemical sproof medicament of platinum-based chemotherapy medicine, wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably, and described method comprises step: the candidate is provided medicament; Described candidate's medicament is contacted with cancerous cell; Detect the expression of the annexin A3 in the described cancerous cell; Detected expression and predetermined threshold are compared.

13. pass through the medicament that the screening technique of claim 12 obtains.

14. chemical sproof method that detects cancerous cell to the platinum-based chemotherapy medicine, wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably, described method comprises the expression that detects the annexin A3 in the cancerous cell, with gained expression and predetermined threshold are compared, indicate the drug resistance of ovarian cancer cell thus to the platinum-based chemotherapy medicine.

15. the prediction or the method for the therapeutic effect of prognosis platinum-based chemotherapy medicine in the cancer patient, wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably, described method comprises the expression of the annexin A3 in the tumor tissues that detects the cancer patient, compare with amount and predetermined threshold gained, the therapeutic effect of platinum-based chemotherapy medicine is used in prediction or prognosis to described patient thus, that is prediction patient's platinum-based chemotherapy drug resistance.

16. claim 12,14 or 15 method, the step that wherein is used to detect annexin A3 expression is implemented by the mRNA level or the protein level that detect annexin A3; Wherein, preferably, the detection on protein level realizes by antibody or oligonucleotide aptamers, preferably utilizes antibody; And the detection on the mRNA level preferably realizes by Northern trace or PCR method.

17. the antibody of specific bond annexin A3 or its Fab, wherein said antibody can be monoclonal antibody or polyclonal antibody, preferably it is a neutralizing antibody.

18. the proteinic oligonucleotide aptamers of specific bond annexin A3, preferably described oligonucleotide aptamers is DNA, preferably, described oligonucleotide aptamers connect or labelling other functional group or molecule, for example sulfydryl, amino, radiosiotope, fluorescein, biotin or enzyme etc.

Be used for detecting the platinum-based chemotherapy drug resistance of cancerous cell or cancer diagnosis patient's the detection of platinum-based chemotherapy drug resistance or the purposes of diagnostic kit in preparation 19. can detect medicament that annexin A3 expresses, wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably, wherein preferably, described medicament is selected from: the antibody of claim 17 or its fragment, the oligonucleotide aptamers of claim 18, be specific to the nucleic probe and the primer of annexin A3 gene, or its combination, more preferably, described medicament is the proteinic antibody of annexin A3, preferred monoclonal antibody.

20. treatment cancer patient's method comprises step: a) change the method for the platinum-based chemotherapy drug resistance of cancer, reduce the toleration of patient to the platinum-based chemotherapy medicine by the present invention; And b) uses the platinum-based chemotherapy medicine to described patient, randomly, the platinum-based chemotherapy Drug tolerance that detects the cancer patient in step (a) before is to determine the drug resistance patient, and wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably.

21. treatment cancer patient's method, described method comprises: the platinum-based chemotherapy drug resistance of determining the patient according to the present invention, with the platinum-based chemotherapy drug administration scheme of adjusting the patient, wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably.

22. compositions, it comprises claim 4,10,13 or 19 described medicaments, preferably, described compositions is used to diagnose and/or change the platinum-based chemotherapy drug resistance of cancer, wherein said cancer is ovarian cancer preferably, more preferably epithelium sample ovarian cancer, described platinum-based chemotherapy medicine is cisplatin or carboplatin preferably.

23. the compositions of claim 22, wherein said pharmacy optimization is selected from: one or any combination in the antibody of claim 6 or 7 antisense nucleotide, claim 8 or 9 ribozyme, claim 17, the oligonucleotide aptamers of claim 18.

24. a method of setting up the strain of platinum-based chemotherapy drug resistance cancer cell comprises: induce cancer cell with heavy dose of platinum-based chemotherapy medicine impact.

25. aforesaid invention, wherein said cancer is the cancer of the enough platinum-based chemotherapy Drug therapys of energy, for example, as ovarian cancer, breast carcinoma, pulmonary carcinoma, tumor of testis, head and neck cancer, osteosarcoma, melanoma, the esophageal carcinoma etc., preferred ovarian cancer, more preferably people's serous ovarian cancer and epithelium sample ovarian cancer comprise inner membrance sample cancer, slurry breast carcinoma, adenocarcinoma, transitional cell carcinoma, carcinoma of endometrium, clear cell carcinoma.

26. aforesaid invention, wherein said platinum-based chemotherapy medicine is cisplatin, carboplatin, JM-216, nedaplatin, happy platinum etc., preferably cisplatin and carboplatin.

Images